Targeting V-ATPase influences cancer cell cholesterol metabolism and biophysical properties - a new option for HCC therapy

Karin Bartel
(geb. Steiner)
aus
München

2017
Erklärung

Eidesstattliche Versicherung
Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfsmittel erarbeitet.

München, den 10.02.2017

________________________
Karin Bartel (geb. Steiner)

Dissertation eingereicht am 10.02.2017
1. Gutachterin Prof. Dr. Angelika M. Vollmar
2. Gutachterin PD Dr. Johanna Liebl
Mündliche Prüfung am 29.03.2017
To my family
CONTENTS
CONTENTS ................................................................................................................. 4

SUMMARY .................................................................................................................... 9

1. INTRODUCTION ................................................................................................... 12
   1.1. Hepatocellular carcinoma .................................................................................. 12
       1.1.1. Risk factors and therapy options .............................................................. 12
       1.1.2. Biomarkers and new strategies for treatment ......................................... 13
   1.2. The V-ATPase in light of cancer treatment ......................................................... 13
       1.2.1. Physiological structure and function of the V-ATPases ......................... 13
       1.2.2. The V-ATPase in cancer ........................................................................ 15
       1.2.3. V-ATPase inhibitors .............................................................................. 15
   1.3. Cholesterol metabolism ..................................................................................... 16
       1.3.1. Cellular cholesterol homeostasis ............................................................. 17
       1.3.2. Cholesterol - an integral membrane molecule with multiple functions ... 18
       1.3.3. Implication of cholesterol metabolism in cancer .................................... 19
   1.4. Oncogenic Ras signaling in HCC ....................................................................... 19
   1.5. Aim of the study ............................................................................................... 21

2. MATERIALS AND METHODS ............................................................................... 23
   2.1. Materials .......................................................................................................... 23
       2.1.1. Compounds .............................................................................................. 23
       2.1.2. Inhibitors, reagents and technical equipment ........................................... 23
       2.1.3. Technical equipment ............................................................................... 25
   2.2. Methods ............................................................................................................ 26
       2.2.1. Cell culture solutions and media .............................................................. 26
       2.2.2. Cell lines, maintenance and passaging ..................................................... 27
       2.2.3. Freezing and thawing .............................................................................. 28
       2.2.4. Transient transfection with small-interfering RNA (siRNA) .................. 28
       2.2.5. Electroporation ....................................................................................... 28
       2.2.6. CellTiter-Blue® cell viability assay ......................................................... 28
       2.2.7. Crystal violet proliferation assay (Clonogenic Assay) ............................. 29
       2.2.8. Immune fluorescence staining ................................................................. 29
       2.2.9. Analysis of membrane polarity ................................................................. 30
       2.2.10. Fluorescence recovery after photo-bleaching (FRAP) ......................... 31
2.2.11. Cholesterol measurement ................................................................. 32
2.2.12. Cholesteryl ester analysis ................................................................. 32
2.2.13. Assessment of apoptosis ................................................................. 32
2.2.14. LDLR surface expression ................................................................. 33
2.2.15. Real-time deformability cytometry (RT-DC) .................................... 33
2.2.16. Western Blot .................................................................................... 34
2.2.17. Ras activity assay ............................................................................ 38
2.2.18. Quantitative real-time PCR (qPCR) ................................................. 38
2.2.19. In vivo HUH-7 xenograft mouse model .......................................... 39
2.2.20. Immune histochemistry (IHC) .......................................................... 39
2.2.21. Statistical Analysis ........................................................................... 40

3. RESULTS .................................................................................................. 42

3.1. V-ATPase inhibition induces cancer cell stiffening and alters membrane fluidity in HCC ................................................................. 42
  3.1.1. Real-time deformability cytometry reveals cancer cell stiffening due to V-ATPase inhibition ................................................................. 42
  3.1.2. V-ATPase inhibition induced cell stiffening due to alterations in membrane properties ................................................................. 44

3.2. V-ATPase inhibition alters cholesterol metabolism of HCC cells .......... 47
  3.2.1. Availability of free cholesterol is diminished upon V-ATPase inhibition . 47
  3.2.2. V-ATPase inhibition impedes internalization of LDL via the LDLR and enhances LDLR expression ......................................................... 48
  3.2.3. V-ATPase inhibition leads to cholesterol trapping and induction of de novo synthesis ................................................................. 51

3.3. Plasma membrane cholesterol depletion leads to impaired Ras signaling.... 53
  3.3.1. Activation of the small GTPase Ras is impaired upon V-ATPase inhibition ................................................................. 53
  3.3.2. Ras downstream signaling is altered upon treatment ......................... 55

3.4. A combination therapy approach to inhibit HCC proliferation ............. 56
  3.4.1. A combination of archazolid and simvastatin leads to synergistic growth inhibition of HCC cells in vitro ......................................................... 56
  3.4.2. Archazolid strongly inhibits tumor growth in an in vivo mouse xenograft model ......................................................................................... 58
4. DISCUSSION .................................................................................................................. 61
   4.1. The V-ATPase influences membrane properties of the cell - and vice versa? 61
   4.2. Cholesterol - an essential factor in cancer cell survival ........................................ 63
   4.3. Blocking cholesterol uptake and synthesis - a combination therapy as promising anti-cancer strategy ............................................................... 64
   4.4. Inhibition of Ras signaling - new treatment option for an old oncogene ........ 66
   4.5. Concluding remarks and future perspectives ....................................................... 69

5. REFERENCES .............................................................................................................. 72

6. APPENDIX ............................................................................................................... 79
   6.1. Abbreviations ...................................................................................................... 79
   6.2. Publications ........................................................................................................ 82
       6.2.1. Articles ....................................................................................................... 82
       6.2.2. Oral presentations ..................................................................................... 82
       6.2.3. Poster presentations .................................................................................. 82
   6.3. Acknowledgements ............................................................................................. 84
Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide and still a major cause of cancer-related death. Despite intensive research, therapy options are limited leaving an urgent need to develop new strategies. Recently, targeting cancer cell lipid and cholesterol metabolism came into focus especially in the context of HCC. Aberrantly increased cholesterol levels cause excessive proliferation, membrane-related mitogenic signaling and a reduction in cell stiffness - factors that favor tumor progression, malignancy and invasive potential. Yet, targeting cholesterol metabolism for cancer therapy is still challenging, leading to a sustained lack of effective therapy options. The V-ATPase inhibitor archazolid was recently implicated in cholesterol metabolism. We report for the first time a novel therapeutic potential of V-ATPase inhibition in cancer by influencing the mechanical phenotype of cancer cells thereby reducing oncogenic Ras signaling. Archazolid inhibits low density lipoprotein (LDL) uptake and induces lysosomal cholesterol trapping, which depletes free cholesterol from the cells and thus leads to an increase in cell stiffness and membrane polarity of cancer cells, while non-malignant hepatocytes remain unaffected. The deficiency of cholesterol in the plasma membrane decreases fluidity and leads to an inhibition of membrane-related Ras signaling resulting in decreased proliferation \textit{in vitro} and \textit{in vivo}. By simultaneous application of the lipid-lowering drug simvastatin, a well characterized inhibitor of \textit{de novo} cholesterol synthesis, a potential escape mechanism by enhanced cholesterol production is prevented, thereby leading to a synergistic growth inhibition \textit{in vitro}. Hence, we present a novel link between cell biophysical properties and proliferative signaling selectively in malignant HCC cells, which can be targeted synergistically by V-ATPase inhibition and blocking cholesterol synthesis, thus building the basis for an attractive and innovative strategy against HCC (Fig 1).
Effects of a combination therapy approach in HCC

Upon inhibition of the V-ATPase by Archazolid (arch), LDLR internalization and acidification of the endo-lysosome is inhibited, causing subsequent accumulation of cholesterol within the lysosomes. Due to blocking the conversion of HMG-CoA to mevalonate by simvastatin (sim), de novo synthesis of free cholesterol is inhibited. The lack of free cholesterol leads to cholesterol depletion of the membrane and subsequently to disruption of cholesterol-enriched microdomains and a change in membrane properties. As a consequence, cholesterol microdomain-dependent Ras cannot be activated anymore and downstream signaling is inhibited, leading to reduced proliferation and tumor growth. Mev Mevalonate, GPP geranylpyrophosphate, FPP farnesylpyrophosphate, Sq squalene, Lano lanosterol, GEF guanosyl-exchange factor, GAP GTPase activating protein, LDL(R) low density lipoprotein (receptor)
INTRODUCTION
1. INTRODUCTION

1.1. Hepatocellular carcinoma

1.1.1. Risk factors and therapy options

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, one of the most frequent cancers worldwide and a major cause of cancer-related death (1-3). The global incident rate of HCC is disproportionate with an increased amount of cases in areas with a high occurrence of hepatitis infections and poor medical care. However, the frequency in the western world is constantly increasing, caused by migration from virus-endemic regions and changes in lifestyle promoting HCC risk factors (4).

![Figure 2 Global incidence of liver cancer](image)

**Figure 2 Global incidence of liver cancer** Incidence of liver cancer in both sexes by geographical region. Age-standardized rate (ASR) of incidence is depicted in blue as a rate of new cases per 100,000 persons per year. Graphic sourced from GLOBOCAN 2012 (5).

The principal causes for the development of HCC are chronic liver diseases and cirrhosis, which are mainly promoted by infection with hepatitis B or C virus. Yet, besides viral hepatitis, alcohol consumption accounts for 40-50 % of HCC cases in Europe. Further conditions like diabetes, obesity, non-alcoholic fatty liver disease, smoking, aflatoxins, hereditary hemochromatosis or male sex increase the risk of developing the malignancy (2).
Despite intensive research, the prognosis remains poor, owing to late-stage diagnosis and limited therapy options. The first choices in treatment of early-stage HCC are liver transplantation and surgical resection; whereas the only approved systemic therapeutic option for late-stage HCC is the kinase inhibitor sorafenib, which extends the median overall survival by 2.8 months (6,7). Additionally, recurrence after transplantation and severe side effects of sorafenib display major problems in treatment.

1.1.2. Biomarkers and new strategies for treatment

In order to fight HCC, numerous studies are ongoing to reveal new therapeutic strategies and to improve diagnostic possibilities. A promising approach is focusing on the metabolic changes that lead to the malignancy, but also are caused by the disease. Several biomarkers have been proposed to serve for surveillance of high-risk patients in diagnosing HCC, such as serum concentrations of α-ferroprotein, des-gamma carboxythrombin, inflammation markers and many more (4). Several studies also report alterations in HCC lipid metabolism that might serve as biomarkers, especially deregulations in fatty acid oxidation and cholesterol metabolism have been observed (4,8). Targeting cancer lipid and cholesterol metabolism pathways has come into focus lately, as deregulation has been reported in various types of cancer cells and patient blood samples (9).

Interestingly, the vacuolar-type ATPase (V-ATPase), a protein in the focus of our research, has been implicated in cholesterol metabolism recently (10) and our group has already shown that V-ATPase inhibition displays anti-cancer properties (11-13). Hence, the V-ATPase seems to be an interesting new target in the treatment of HCC.

1.2. The V-ATPase in light of cancer treatment

1.2.1. Physiological structure and function of the V-ATPases

V-ATPases are large multi-subunit protein complexes expressed in a variety of cellular membranes, especially in the endo-lysosomal system. The V-ATPases are ATP-dependent proton pumps and are primarily responsible for maintaining pH homeostasis by regulation of the proton concentration in intracellular organelles. Basically, the V-ATPase consists of two functional domains (Fig 3): the V_1 domain, which is located at the cytosolic side of the membrane and exerts ATP hydrolysis to generate energy for the second domain, and the V_0 domain, which is integrated in the membrane and responsible for proton translocation (14,15). Both domains are
composed of a variety of different smaller subunits. In $V_1$, the A and B subunits create the catalytic sites for ATP hydrolysis and the C-H subunits form central and peripheral stalk. Following energy generation, the $V_0$ domain moves in a rotatory fashion and protons bound to the domain can be released to the luminal side (14,16).

**Figure 3 Structure of the V-ATPase** The V-ATPase consists of two functional domains: the $V_1$ domain and the $V_0$ domain. The cytosolic $V_1$ domain is built by eight subunits A-F with A and B forming the catalytic sites for ATP hydrolysis (one site per AB heterodimer), C-H forming the peripheral stalk that keeps $V_1$ in its place and DF forming the central stalk which couples the energy to the $V_0$ domain. The membrane integral $V_0$ domain consists of subunits a,d,e and 4 copies of c. The c subunits form a membrane integral proteolipid ring and subunit a contains a hemichannel for proton ($H^+$) translocation. The proteolipid ring rotates subsequently to energy generation in $V_1$ domain, thereby enabling proton release to the luminal side. Illustration according to the model of Forgac et al. 2007 (14).

Consequentially to their function as proton pumps, V-ATPases play a crucial role in physiological processes like receptor-mediated endocytosis, membrane trafficking and recycling. Specialized cells also express the V-ATPase on their plasma membrane in order to acidify the extracellular space, important e.g. in the renal tube or in the process of bone resorption (14,17).
1.2.2. The V-ATPase in cancer

Expressing V-ATPase at the plasma membrane is also a feature reported for cancer cells. The extracellular space of tumors has been shown to display low pH provided by the V-ATPase, a metabolic status favoring migration and invasion of several cancer types including HCC. In this regard, V-ATPase expression at the plasma membrane was correlated with metastatic potential of cancer cells. (17-22)

Recently, the V-ATPase has emerged as promising anti-cancer target as inhibition leads to apoptosis induction of a variety of cancer cells. In this regard, our group could demonstrate that inhibition of epidermal growth factor receptor (EGFR) and transferrin receptor recycling by blocking V-ATPase function leads to an inhibition in cancer cell migration and induction of apoptotic cell death in highly metastatic cancer cells (11,12,23). Interestingly, Hamm et al. recently found first evidence that V-ATPase inhibition affects cholesterol homeostasis in cancer cells (24), a function that provides the possibility to be exploited for treatment of cancers relying on altered lipid metabolism.

1.2.3. V-ATPase inhibitors

As it has been shown that V-ATPase function is important for migration and survival of various cancer cells, inhibitors of the proton pump came into focus for anti-cancer therapies.

Since the early 1980s, the plecomacrolides bafilomycin and concanamycin which were isolated from Streptomyces species have been known to inhibit the V-ATPase. While bafilomycin was the first described inhibitor, concanamycin showed higher specificity. The plecomacrolides bind to the c subunit of the proteolipid ring thereby preventing rotation and proton translocation. (25,26) Further research in the late 1990s revealed the benzolactone enamides (e.g. salicylihalamide, apicularen) as inhibitors with IC$_{50}$ values in the nanomolar range (27). Efforts to simplify structures of V-ATPase inhibitors brought forth the synthetic indolyls, which are widely used for research due to the possibility of modification for different biophysical approaches (28,29).
Another highly potent inhibitor is archazolid (Fig 4), a myxobacterial secondary metabolite with IC$_{50}$ values in the low nanomolar range. Archazolid was isolated from the strains *Archangium gephyra* and *Cystobacter violaceus* and its total synthesis has been published several years ago (30-33). Archazolid is a macrocyclic lactone that binds to the equatorial region of the c subunit thereby inhibiting rotation and proton translocation similar to plecomacrolides (27). As it is an inhibitor with high specificity and affinity as well as proven anti-cancer activity, we used it as a tool for studying V-ATPase in HCC.

![Figure 4 Structure of archazolid A adapted from Huss et al. 2009 (27).](image)

### 1.3. Cholesterol metabolism

Cholesterol is a molecule of central importance in the human body and as such has been intensively studied for a long time. It is an essential component of the membrane barrier influencing its fluidity, the function of membrane proteins and transmembrane signaling processes (34). Furthermore, cholesterol is a precursor for steroids and bile acids, which have important biological roles in signal transduction and regulation of other lipids. Owing to its various functions, de-regulation in cholesterol homeostasis is implicated in many serious diseases like atherosclerosis, diabetes and cancer (34,35). Hence, cholesterol metabolism is extensively regulated.
1.3.1. **Cellular cholesterol homeostasis**

In principle, cellular cholesterol homeostasis is regulated by synthesis, influx and efflux. Eukaryotic cells can synthesize cholesterol in the endoplasmatic reticulum (ER), utilizing the mevalonate pathway starting from Acetyl-CoA. The rate-limiting step of the *de novo* synthesis is the reduction of HMG-CoA to mevalonate catalyzed by the HMG-CoA reductase (HMGCR), the direct target of statins. (34-36) Apart from their indication as lipid-lowering agents, statins were also tested in several studies for the use as anti-cancer agents, but until now with controversial outcome (37,38).

**Figure 5 Cholesterol synthesis pathway** Starting from Acetyl-CoA, HMG-CoA is synthesized via multiple enzymatic reactions. The subsequent reduction of HMG-CoA to mevalonate, catalyzed by the HMGCR, is the rate-limiting step of the following synthesis. After further multiple reactions, farnesyl-PP is synthesized, which is used to generate additional important metabolites with distinct cellular functions. Cholesterol is synthesized in a complex pathway facilitating demethylations and double bond reductions in about 20 different reactions from lanosterol. Cholesterol is then further metabolized or used as membrane building block. Illustrated according to Ikonen and Thurnher (34,36). Dashed lines between molecules (blue boxes) indicate multiple reactions; PP pyrophosphate; grey boxes list sequential functions and products.

The second important way for cells to increase their cholesterol content is the internalization of cholesterol-containing lipoproteins mainly via the low-density lipoprotein receptor (LDLR) pathway. Dietary cholesterol is absorbed in the small intestine and transported to hepatocytes that provide the body with very low-density lipoprotein (VLDL). In the circulation VLDL is processed to LDL, which can bind to the LDLR on the surface of cells. The complex is then internalized and cleaved in the
acidic environment of the endo-lysosomal system. The LDLR is recycled back to the cellular surface and free cholesterol is released into the cytosol. (35,39)

Figure 6 LDL internalization LDL (green) from the circulation binds to the LDLR on the outer surface of the plasma membrane. The complex is internalized into the endo-lysosomal system. In the acidic environment of the lysosome, created by the V-ATPase, LDL dissociates from the receptor, is cleaved and free cholesterol (blue) is released into the cytosol.

While excess cholesterol is esterified for intracellular storage or externalized, free cholesterol is further metabolized or integrated into membranes.

1.3.2. Cholesterol - an integral membrane molecule with multiple functions

Cholesterol is one of the main components of mammalian cell membranes with a molar proportion of up to 50 % in the plasma membrane (40). Probably the most important function of membrane cholesterol is to modulate biophysical properties by increasing order. Integration of cholesterol between phospholipids decreases mobility of phospholipids and raises the packing density within the membrane, thereby influencing mechanical strength and fluidity (41).

Yet, cholesterol is heterogeneously present within intracellular membranes, while 40-90 % of cellular free cholesterol is integrated into the plasma membrane, mitochondria for instance only contain about 0.5-3 % of the cholesterol concentration.
and golgi membranes show intermediate levels (41-43). This indicates additional functions for membrane cholesterol. There exist small areas within membranes that are especially rich in cholesterol and sphingolipids and display a very high membrane order, the lipid-rafts. These distinct microdomains also contain transmembrane and membrane-integrated proteins essentially involved in signal transduction. (44,45) Lipid-rafts have been shown to regulate activity of enzymes and to influence ion channels and membrane receptors, thereby modulating proliferation and signaling (40,41,45,46).

1.3.3. Implication of cholesterol metabolism in cancer

Given the functions of cholesterol, it is not surprising that alterations in cholesterol metabolism have been shown both to occur in and to influence cancer cells. Cholesterol is an important player in the development of malignancy. High cholesterol levels in cancer cells are known to be beneficial for tumor progression and drug resistance and it has been reported that alterations in cholesterol levels of primary tumor cells and HCC cell lines were linked with chemotherapy resistance and protection from apoptosis (9,47).

Lately, increasing evidence suggests that the loss of cell stiffness correlates with the malignancy and invasive potential of cancer cells. Studies have shown that cancer cells are softer than their non-malignant counterparts, which seems to correlate with metastasis, invasion and tumor stage (40,46). Furthermore evidence increases that de-regulated cholesterol metabolism in cancer cells influences intracellular signaling (48,49). Cholesterol metabolism therefore emerged as a promising target in the combat to find new anti-cancer treatment options.

1.4. Oncogenic Ras signaling in HCC

The small GTPase Ras is a well-known oncogene mutated in 20 % of all tumors, and has been shown to be an oncogene excessively activated in HCC (50,51). Interestingly, recent research suggests that cholesterol content of the plasma membrane influences signaling pathways, like e.g. Ras signaling, and therefore might be of interest when considering aberrant Ras signaling in cancer (52).

In HCC, genetic mutations in Ras or the downstream effector Raf are rare compared to other tumor types; however activation of the Ras downstream pathways commonly occurs through dysregulation of Ras activators or inhibitors (53,54). In general, increased activity of Ras displays poor prognosis for cancer patients.
The activation state of Ras is dependent on the binding status of guanosine diphosphate (GDP) or guanosine triphosphate (GTP). Inactive Ras is bound to GDP, which is exchanged for GTP by guanosyl-exchange factors (GEFs) such as SOS. Activation of GEFs is for example facilitated by the binding of growth factors to their receptor on the cell surface. GEFs are then recruited to the plasma membrane to activate Ras. GTP-bound Ras in turn activates various downstream signaling cascades like the MAPK or PI3K pathway, which ultimately lead to transcription of cell proliferation-, migration-, survival-, differentiation- and mesenchymal-epithelial-transition-related target genes (50,53).

**Figure 7 Activation of Ras downstream signaling** Upon binding of a growth factor like EGF to its respective receptor on the cell surface, receptor downstream signaling is initiated. In case of the EGF, the receptor dimerizes and undergoes autophosphorylation. Subsequently, the guanosyl-exchange factor (GEF) SOS and the adapter protein GRB2 are recruited. GEFs exchange GDP bound to Ras for GTP, which leads to an activation at cholesterol-rich membrane sites. Activated Ras in turn activates various downstream signaling pathways that lead to distinct functions, as depicted in the respective boxes. Deactivation of Ras is facilitated by GTP-ase activating proteins (GAPs) that exchange GTP for GDP. Blue circles represent cholesterol. Illustration adapted from Delire et al. 2015 and Downward et al. 2013 (50,53).
1.5. **Aim of the study**

Our group has previously introduced the potent V-ATPase inhibitor archazolid as an interesting and effective anti-cancer agent and unraveled different aspects of its mechanism of action (11-13,23). Interestingly, there is initial evidence now that V-ATPase inhibition affects cholesterol homeostasis in cancer cells (24).

In the present study we aim to specifically target cancer cell cholesterol metabolism by archazolid single treatment and furthermore in a combination therapy approach together with simvastatin. We want to

- analyze the effect of V-ATPase inhibition on cell biophysical properties
- investigate the role of V-ATPase in cholesterol regulation
- assess possible consequences on cell survival
- and reveal underlying mechanisms

in order to find new strategies for the treatment of HCC (Fig 8).

**Figure 8 Study objectives** The study aims to use archazolid A as a tool to investigate the influence of V-ATPase inhibition on cellular biophysics, cholesterol metabolism and cell survival in order to find new treatment strategies for HCC.
MATERIALS AND METHODS
2. MATERIALS AND METHODS

2.1. Materials

2.1.1. Compounds

The myxobacterial compound archazolid A was provided by Rolf Müller (Saarland University) and simvastatin was purchased from Sigma-Aldrich. The compounds were dissolved to 10 mM stock solutions in DMSO and stored at -20 °C. As the final DMSO concentration in the experiments did not exceed 0.1 %, possible DMSO side effects could be excluded.

2.1.2. Inhibitors, reagents and technical equipment

Table 1 Biochemicals, dyes, inhibitors, kits and cell culture reagents

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Producer</th>
</tr>
</thead>
<tbody>
<tr>
<td>5x siRNA Buffer</td>
<td>Dharmacon™, GE Healthcare, USA</td>
</tr>
<tr>
<td>Amaza™ Cell Line Nucleofector™ Kit T</td>
<td>Lonza Cologne AG, Cologne, Germany</td>
</tr>
<tr>
<td>Amplex® Red Cholesterol Assay Kit</td>
<td>Molecular Probes Inc., Thermo Fisher, Eugene, OR, USA</td>
</tr>
<tr>
<td>BC Assay reagent</td>
<td>Interdim, Montulocon, France</td>
</tr>
<tr>
<td>Bovine serum albumin</td>
<td>Sigma-Aldrich, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Cell-Titer Blue™</td>
<td>Promega, Madison, WI, USA</td>
</tr>
<tr>
<td>Collagen A/G</td>
<td>Biochrom AG, Berlin, Germany</td>
</tr>
<tr>
<td>Complete® EDTA free</td>
<td>Roche Diagnostics, Penzberg, Germany</td>
</tr>
<tr>
<td>Crystal violet</td>
<td>Carl Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Dithiotheritol (DTT)</td>
<td>AppliChem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Dulbecco’s Modified Eagle Medium (DMEM)</td>
<td>PAA Laboratories, Pasching, Austria</td>
</tr>
<tr>
<td>DMSO</td>
<td>Sigma-Aldrich, Taufkirchen, Germany</td>
</tr>
<tr>
<td>EDTA</td>
<td>Carl Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>EGTA</td>
<td>Sigma-Aldrich, Taufkirchen, Germany</td>
</tr>
<tr>
<td>EGF</td>
<td>Peprotech, Rocky Hill, USA</td>
</tr>
<tr>
<td>FCS</td>
<td>Biochrom AG, Berlin, Germany</td>
</tr>
</tbody>
</table>
MATERIALS AND METHODS

FluorSave™ Reagent
Formaldehyde 16 %, ultrapure
GlutaMAX™

HepaRG™ Thaw, Plate, & General Purpose Medium Supplement
HepaRG™ Maintenance/Metabolism Medium Supplement
High-Capacity cDNA Reverse Transcription Kit
Hoechst 33342
Igepal CA 630 (Nonidet P 40)
Na₃VO₄
NaCl
NaF
Non-fat dry milk powder (Blotto)
Page-Ruler™ Prestained Protein Ladder
Penicillin/Streptomycin (P/S)
PFA
PMSF
Polyacrylamid
PowerUp™ SYBR Green Master Mix
Propidium iodide
Qiagen RNasey Mini Kit
Ras Activation Kit ab128504
Sodiumdodecylsulfate (SDS)
TCE
Tris Base/HCl
Trisodium citrate dicydrate
Triton X-100
Trypsin
Tween 20
VECTASTAIN Elite ABC HRP Kit

Merck, Darmstadt, Germany
Polysciences, Eppelheim, Germany
Life Technologies, Thermo Fisher, Carlsbad, CA, USA
Life Technologies, Thermo Fisher, Carlsbad, CA, USA
Life Technologies, Thermo Fisher, Carlsbad, CA, USA
Applied Biosystems, Foster City, CA, USA
Sigma-Aldrich, Taufkirchen, Germany
Sigma-Aldrich, Taufkirchen, Germany
ICN Biomedicals, Aurora, Ohio, USA
Sigma-Aldrich, Taufkirchen, Germany
Merck, Darmstadt, Germany
Fermentas, St. Leon-Rot, Germany
PAA Laboratories, Pasching, Austria
Sigma Aldrich, Taufkirchen, Germany
Sigma Aldrich, Taufkirchen, Germany
Carl Roth, Karlsruhe, Germany
Applied Biosystems, Foster City, CA, USA
Sigma-Aldrich, Taufkirchen, Germany
Qiagen, Hilden, Germany
Abcam, Cambridge, UK
Carl Roth, Karlsruhe, Germany
Sigma-Aldrich, Taufkirchen, Germany
Sigma-Aldrich, Taufkirchen, Germany
Sigma-Aldrich, Taufkirchen, Germany
Merck, Darmstadt, Germany
PAN Biotech, Aidenbach, Germany
Bio-Rad, Munich, Germany
Vectorlaboratories, Burlingame, CA,
(Peroxidase, Universal) USA
ImmPACT AEC Peroxidase (HRP) Vectorlaboratories, Burlingame, CA, USA
Substrate USA
William’s E-Medium Life Technologies, Thermo Fisher, Carlsbad, CA, USA

2.1.3. Technical equipment

Table 2 Technical equipment

<table>
<thead>
<tr>
<th>Technical equipment</th>
<th>Producer /Distributor</th>
</tr>
</thead>
<tbody>
<tr>
<td>7300 Real Time-PCR System</td>
<td>applied Biosystems, ThermoFisher PCR, Scientific, Waltham, MA, USA</td>
</tr>
<tr>
<td>Axiovert 25</td>
<td>Zeiss, Oberkochen, Germany</td>
</tr>
<tr>
<td>BD FACS Canto™ II</td>
<td>BD Biosciences, Heidelberg, Germany</td>
</tr>
<tr>
<td>Canon EOS 450C camera</td>
<td>Canon, Tokyo, Japan</td>
</tr>
<tr>
<td>ChemiDoc™ Touch Imaging system</td>
<td>Bio-Rad, Hercules, CA, USA</td>
</tr>
<tr>
<td>Consort Electrophoresis Power Supply E835</td>
<td>Sigma-Aldrich, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Curix 60</td>
<td>Agfa, Cologne, Germany</td>
</tr>
<tr>
<td>ibiTreat μ-slide 8-well</td>
<td>ibidi GmbH, Munich, Germany</td>
</tr>
<tr>
<td>Leica-SP8 confocal microscope</td>
<td>Leica Microsystems Inc., IL, USA</td>
</tr>
<tr>
<td>Mikro 22R centrifuge</td>
<td>Hettich, Tuttingen, Germany</td>
</tr>
<tr>
<td>Mini-PROTEAN 3</td>
<td>Bio-Rad, Munich, Germany</td>
</tr>
<tr>
<td>Nanodrop® ND-1000</td>
<td>Peqlab, Wilmington, DE, USA</td>
</tr>
<tr>
<td>Nucleofector™II Device</td>
<td>Lonza, Basel, Switzerland</td>
</tr>
<tr>
<td>Odyssey 2.1</td>
<td>LI-COR Biosciences, Lincoln, NE, USA</td>
</tr>
<tr>
<td>Olympus CK30 and BX41</td>
<td>Olympus Deutschland GmbH, Hamburg, Germany</td>
</tr>
<tr>
<td>Primus 25 advanced® Thermocycler</td>
<td>PeQlab, Erlangen, Germany</td>
</tr>
<tr>
<td>PVDF Blotting Membrane 0.2 µm</td>
<td>Amersham™ Hybond™, GE Healthcare, Life science, Germany</td>
</tr>
<tr>
<td>QuantStudio® 3 Real-Time Instrument (96-Well 0.1 ml Block)</td>
<td>applied biosystems, ThermoFisher PCR, Scientific, Waltham, MA, USA</td>
</tr>
<tr>
<td>Rotational Vacuum Concentrator RVC</td>
<td>Martin Christ Gefriertrocknungsanlagen</td>
</tr>
</tbody>
</table>
2.2. Methods

2.2.1. Cell culture solutions and media

The following solutions and reagents were used for cultivation and maintenance.

<table>
<thead>
<tr>
<th>PBS (pH 7.4)</th>
<th>PBS + Ca(^{2+})/Mg(^{2+}) (pH 7.4)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NaCl</strong></td>
<td>132.2 mM</td>
</tr>
<tr>
<td><strong>Na(_2)HPO(_4)</strong></td>
<td>10.4 mM</td>
</tr>
<tr>
<td><strong>KH(_2)PO(_4)</strong></td>
<td>3.2 mM</td>
</tr>
<tr>
<td>in H(_2)O</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DMEM++</th>
<th></th>
<th>Trypsin/EDTA (T/E)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMEM</td>
<td>500 ml</td>
<td>Trypsin</td>
</tr>
<tr>
<td>FCS</td>
<td>10 %</td>
<td>EDTA</td>
</tr>
<tr>
<td>P/S</td>
<td>1 %</td>
<td>in PBS</td>
</tr>
</tbody>
</table>
FCS was inactivated by partially thawing for 30 min at room temperature, totally thawing at 37 °C and finally incubating at 56 °C for 30 min. FCS aliquots were stored at -20 °C.

2.2.2. Cell lines, maintenance and passaging

HUH7 and HepG2 cells were obtained from Japanese Collection of Research Bioresources (JCRB) and German Research Centre of Biological Material (DSMZ) (ACC180), respectively. Cell line STR profiling was performed. HCC cells were grown in DMEM++. HepaRG™ cells were obtained from Life Technologies. Cells were plated and maintained in Williams’ medium E supplemented with GlutaMAX™ and HepaRG™ Thaw, Plate, & General Purpose Medium Supplement (Thaw, Plate, & General Purpose Working Medium) purchased from Life Technologies. For metabolism studies, cells were seeded in Thaw, Plate, & General Purpose Working Medium, which was replaced by in Williams’ medium E supplemented with GlutaMAX™ and HepaRG™ Maintenance/Metabolism Medium Supplement (Metabolism Medium) after 24 h. Thereafter medium was renewed every 3 days. Experiments were performed after 7 days of cell maintenance in Metabolism Medium. Primary human hepatocyte tissue samples (hHep) and annotated data were obtained and experimental procedures were performed within the framework of the non-profit foundation HTCR, including the informed patient’s consent. For experiments hHep were cultivated in DMEM++. All cells were cultured under constant humidity at 37 °C and with 5 % CO₂ in an incubator. All culture flasks, multiwell-plates and dishes were first coated with collagen G before seeding the cells. Cells were routinely tested for contamination with mycoplasma using PCR detection kit VenorGeM (Minerva Biolabs).

After reaching confluency, growth medium was removed, cells were washed twice with pre-warmed PBS and detached by incubation with pre-warmed T/E for approximately 5 min at 37 °C. Digestion was stopped by adding 10 ml growth medium, cells were centrifuged (1000 rpm, 5 min), resuspended in medium, counted and plated for the respective experiments. All plates and dishes were pre-coated with
MATERIALS AND METHODS

2.2.3. Freezing and thawing

For long-term storage, cells were detached, counted and 2x10^6 HCC cells or 4x10^6 HepaRG™ were resuspended in 1 ml growth medium supplemented with 20 % FCS, 1 % P/S and 20 % DMSO. Cells were transferred into cryo vials and immediately frozen at -20 °C for 24 h, transferred to -80 °C for at least 6 h and finally to liquid nitrogen for long-term storage. For thawing, the frozen cells were warmed up in a water bath to 37 °C and transferred into 5 ml growth medium. The cells were pelleted and the supernatant was discarded to remove DMSO. Subsequently cells were resuspended in growth medium and placed into a 25 cm² culture flask. The following day, growth medium was changed and the cells were left to reach confluency.

2.2.4. Transient transfection with small-interfering RNA (siRNA)

For silencing experiments, cells were seeded 24 h prior to transfection with siRNA using DharmaFECT™ transfection reagents and manufacturer’s protocol (Dharmacon™, GE Healthcare). The c-subunit of the V-ATPase (ATP6V0C) was silenced using ON-TARGETPlus SMARTpool siRNA (2 µg) and non-targeting siRNA (nt siRNA) as a control (Dharmacon™, GE Healthcare). 48 h after transfections cells were harvested for the respective assay.

2.2.5. Electroporation

Plasmid transfection was performed by electroporation according to manufacturer’s instruction using Amaxa™ Cell Line Nucleofector™ Kit T. In brief, cells were detached, counted and 2x10^6 cells were transferred into a tube, centrifuged and the supernatant was discarded. The cells were resuspended in 100 µl Nucleofector™ solution and 2 µg plasmid were added. The cell suspension was transferred into a cuvette and transfected using the T-28 program. The transfected cells were transferred into medium and plated for the respective assay.

2.2.6. CellTiter-Blue® cell viability assay

The metabolic capacity of cells can be considered as an indicator for their viability. To analyze viability, the CellTiter-Blue® cell viability assay (Promega) was employed, which uses the indicator dye resazurin.
MATERIALS AND METHODS

Figure 9 CellTiter-Blue® cell viability assay reaction In viable cells resazurin (left) is reduced to resorufin (right), which shows fluorescence at 590 nm.

Therefore 5,000 cells/well were seeded into 96-well plates and allowed to adhere overnight. Before stimulation initial metabolic activity was determined and cells were treated as indicated for 72 h. 4 h before end of stimulation time CellTiter-Blue® Reagent was added and the fluorescence at 590 nm was measured with the SpectraFluor Plus™ plate reader. The fluorescence is proportional to the cell number.

2.2.7. Crystal violet proliferation assay (Clonogenic Assay)

For the evaluation of long-term effects on proliferation of HUH7 cells, a clonogenic assay was performed. HUH7 cells were seeded, left to adhere for 24 h and treated as indicated for 24 h. After stimulation time, cells were detached and reseeded at a density of 10,000 cells/well on a 6-well plate. After 7 days cells were stained with 1 ml 0.5 % crystal violet solution for 10 min at room temperature. After removal of the dye and five washing steps with distilled water, cells were imaged at 10x magnification. Subsequently, 1 ml dissolving buffer/well was added and absorbance at 550 nm was measured with the SpectraFluor Plus™ plate reader.

Table 4 Clonogenic assay solutions

<table>
<thead>
<tr>
<th>Crystal violet solution</th>
<th>Dissolving buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crystal violet</td>
<td>Trisodium citrate</td>
</tr>
<tr>
<td>5 % (w/v)</td>
<td>20 mM</td>
</tr>
<tr>
<td>Methanol</td>
<td>Ethanol</td>
</tr>
<tr>
<td>20 %</td>
<td>50 %</td>
</tr>
<tr>
<td>in H₂O</td>
<td>in H₂O</td>
</tr>
</tbody>
</table>

2.2.8. Immune fluorescence staining

To stain HUH7 cells for confocal microscopy 20,000 cells/well were seeded on ibiTreat μ-slide 8-well slides one day prior to treatment as indicated. After treatment, cells were washed with PBS, fixed with 3 % Paraformaldehyde (PFA) for 30 min, permeabilized with 0.1 % triton-X and unspecific binding was blocked with 2 % BSA.
Subsequently, the proteins of interest were bound with specific antibodies for 2 h at 25 °C or at 4 °C overnight and visualized with fluorescent secondary antibodies for 45 min at 25 °C. Cholesterol was stained with 50 µg/ml filipin (Sigma Aldrich) for 2 h at 25 °C. Nuclei were stained with TO-PRO®3 or Hoechst. Actin was stained with rhodamine-phalloidin. Cells were washed and mounted with FluorSave™ Reagent mounting medium and covered with a glass coverslip. Images were taken by confocal microscopy.

Table 5 Primary antibodies for confocal microscopy

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Company</th>
<th>Cat. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAMP-1</td>
<td>Developmental Studies</td>
<td>H4A3</td>
</tr>
<tr>
<td></td>
<td>Hybridoma Bank</td>
<td></td>
</tr>
<tr>
<td>LDLR</td>
<td>Santa Cruz</td>
<td>sc-18823</td>
</tr>
</tbody>
</table>

Table 6 Secondary antibodies and dyes for confocal microscopy

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Company</th>
<th>Cat. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse IgG (AlexaFluor 488 conjugate)</td>
<td>Life Technologies</td>
<td>A - 11001</td>
</tr>
<tr>
<td>TO-PRO®3</td>
<td>Life Technologies</td>
<td>T3605</td>
</tr>
<tr>
<td>Filipin</td>
<td>Sigma Aldrich</td>
<td>F4767</td>
</tr>
<tr>
<td>di-4-AEPPDHQ</td>
<td>Life Technologies</td>
<td>D36802</td>
</tr>
<tr>
<td>Rhodamine-Phalloidin</td>
<td>Life Technologies</td>
<td>R-415</td>
</tr>
<tr>
<td>DilLDL</td>
<td>Life Technologies</td>
<td>L3482</td>
</tr>
<tr>
<td>Hoechst 33342</td>
<td>Sigma Aldrich</td>
<td>H6024</td>
</tr>
</tbody>
</table>

2.2.9. Analysis of membrane polarity

For analysis of membrane polarity, 20,000 cells/well were seeded on ibiTreat μ-slide 8-well slides 24 h prior to stimulation. The cells were treated as indicated for 24 h. Subsequently, medium was exchanged for DMEM without FCS containing 10 µM of the dye di-4-AEPPDHQ for 30 min at 37 °C. Live cell imaging was performed as described previously using a Leica TCS SP 8 SMD confocal microscope with a top stage incubator (Oko Lab, Ottaviano, Italy). In brief, the dye intercalates into membranes and changes its emission spectrum due to polarity of the environment. By calculating the ratio (generalized polarization, GP) of light intensities between the channels membrane polarity can be analyzed.
Figure 10 Fluorescence properties of di-4-ANEPPDHQ After excitation at 488 nm (blue line), the dye fluoresces either with a peak emission around ~560 nm (green line) when residing in less polar environment, or at ~620 nm in the rather polar disordered phase (red line). Both wavelength bands indicated by the shaded boxes are detected by two channels. Image adapted from Owen et al. (55).

For analysis of the images a macro for ImageJ (ImageJ 1.46r, NIH, USA) based on the one provided by Owen et al. (55) was used designed with the kind help of Erwin Steiner. Statistical evaluation of GP value distribution was performed with GraphPad Prism.

2.2.10. Fluorescence recovery after photo-bleaching (FRAP)

24 h prior to treatment as indicated, HUH7 cells were transfected with a plasmid coding for farnesylated GFP (pAcGFP-C1, Clontech). Electroporation using Amaxa® Cell Line Nucleofector® Kit T (program T-28) as described in 2.2.5 was employed. 40,000 cells per well were subsequently seeded onto ibiTreat μ-slide 8-well slides and FRAP assay was performed using a Leica TCS SP 8 SMD confocal microscope with a top stage incubator (Oko Lab). A defined region of interest was bleached with high laser power and recovery of the GFP signal was monitored by recording 60 post bleach images every 10 s.

Figure 11 Plasmid vector information for pAcGFP1-F Adapted from manufacturer’s product information (Catalog No. 632511 pAcGFP1-F, Clontech, CA, USA).
2.2.11. Cholesterol measurement

Cellular cholesterol levels were measured using the Amplex® Red Cholesterol Assay Kit according to manufacturer’s protocol. The assay is based on an enzyme-coupled reaction that detects both free cholesterol and esterified cholesterol by generating \( \text{H}_2\text{O}_2 \) that is subsequently detected using 10-acetyl-3,7-dihydroxyphenoxazine (Amplex® Red reagent). Therefore, cells were treated as indicated for 48 h, detached and either homogenized right away in a lipid extraction solution containing chloroform, isopropanol and IGEPA CA-630 (7:11:0.1) via sonication, or homogenization was performed on lysosomes isolated as described previously (56). After centrifugation (13,000x g, 10 min) the organic phase was air dried at 50 °C for 10 min to remove chloroform. Remaining organic solvent was removed by vacuum at 30 °C for 30 min. Dried lipids were dissolved in 1x assay reaction buffer and mixed 1:1 with a working solution containing 300 µM Amplex® Red reagent, 2 U/ml horseradish peroxidase (HRP), 2 U/ml cholesterol oxidase and in case of total cholesterol measurement 0.2 U/ml cholesterol esterase. After incubation for 30 min at 37 °C fluorescence was measured with the SpectraFluor Plus™ plate reader.

2.2.12. Cholesteryl ester analysis

HUH-7 cells were treated as indicated, trypsinized and collected by centrifugation. The cell pellet was frozen in liquid nitrogen and stored at -80 °C until use. The pellet was resuspended in methanol, chloroform was added and finally PBS. Cells were then centrifuged at 4000 rpm for 5 min and lower chloroform phase was collected. The chloroform was evaporated for 20 min at 30 °C and dried lipids were dissolved in methanol. After centrifugation at 1500 rpm for 5 min, supernatant was diluted with methanol, centrifuged again at 1500 rpm for 5 min and analysed by LC-MS/MS, as described previously (57).

2.2.13. Assessment of apoptosis

Apoptosis was analyzed according to the method described by Nicoletti et al. (58). In this assay, the subG1 population, which is characteristic for DNA fragmentation and loss of nuclear DNA, is evaluated. For this purpose, cells were detached, washed with PBS and resuspended in 100 µl flow cytometry solution, containing propidium iodide (PI) and incubated for 30 min at 4 °C. Apoptotic DNA was determined by flow cytometry using BD FACS Canto™ II. For data evaluation the flow cytometry analysis software FlowJo 7.6 was employed.
Table 7 Flow cytometry solution

<table>
<thead>
<tr>
<th>Flow cytometry solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propidium iodide</td>
</tr>
<tr>
<td>Trisodium citrate</td>
</tr>
<tr>
<td>Triton-X 100</td>
</tr>
<tr>
<td>in PBS</td>
</tr>
</tbody>
</table>

2.2.14. LDLR surface expression

Cells were treated as indicated for 24 h. After stimulation, growth medium was removed and the cells were washed twice with pre-warmed PBS before trypsination, washed again with PBS once and incubated with anti-LDLR antibody (sc-18823, santa cruz) for 45 min at room temperature. After washing, secondary antibody conjugated to AlexaFluor 488 was added for 45 min at room temperature and after two additional washing steps, cells were analyzed by flow cytometry with a FACSCanto II cytometer.

2.2.15. Real-time deformability cytometry (RT-DC)

For RT-DC measurements the experimental setup has been described earlier (59). Cells were trypsinated and resuspended to a final concentration of about $3 \times 10^6$ cells/ml in 0.5 % methylcellulose solved in PBS. To achieve cell deformation the cell suspension was pumped through a microfluidic chip containing a constricted channel of 30 µm x 30 µm at flow rates of 0.16 µl/s, 0.24 µl/s and 0.32 µl/s.

Figure 12 Schematic setup of RT-DC assay setup Image adapted from Otto et al. (59).

As a reference, non-deformed cells were measured outside the channel in the reservoir where cell deformation does not take place. Cell size (cross-sectional area) and deformation ($1 - \text{circularity}$) was determined in real-time for $>3000$ cells per
experiment at rates of 100 cells/sec. Isoelasticity lines were assessed as reported elsewhere (60).

\[ RD = \frac{(d_{\text{treat chan}} - d_{\text{treat res}})}{(d_{\text{chan}} - d_{\text{res}})} \]

**Figure 13 Calculation of relative deformation** RD relative deformation, \(d_{\text{treat chan}}\) deformation of the treated samples in the channel, \(d_{\text{treat res}}\) deformation of the treated samples in the reservoir, \(d_{\text{chan}}\) deformation of the control samples in the channel, \(d_{\text{res}}\) deformation of the control samples in the reservoir

Statistical analysis was performed by applying linear mixed effects models. Therefore, a fixed effects model is extended by a random effect term that can be used to account for error induced by the experimental design. The archazolid A treatment was considered as a binary fixed effect whereas biological variations between experiments were taken as a random effect. We allowed the model to fit random intercepts to attribute for variations in the mean values of the control group as well as random interslopes to account for variable differences between the control and the archazolid A-treated group. \(p\) values were calculated by a likelihood ratio test.

2.2.16. Western Blot

For analysis of protein levels, Western blot analysis was performed. Firstly, in case of total cell lysates, the cells were lysed using RIPA lysis buffer and freezing cells at -80 °C. In case of subcellular analysis of proteins, cells were fractionated into cytosolic, membrane, mitochondrial and nuclei fraction. Therefore, cells were washed with PBS, 500 μl of buffer A were added and cells were scraped off plates. Subsequently, the lysate was passed through a 25 Ga needle 10x using a 1 ml syringe. After incubation on ice for 20 min, the nuclear pellet was centrifuged out at 720xg for 5 min at 4 °C. The nuclear pellet was washed once with buffer A, resuspended in buffer B and sonicated briefly. The remaining supernatant was centrifuged at 10,000xg, the pellet represents mitochondrial fraction. The superanatant was transferred to ultracentrifugation at 100,000xg for 1 h at 4 °C. The resulting pellet displays the membrane fraction, which was washed once with
buffer A, then dissolved in buffer B and sonicated briefly. The remaining lysate represents the cytosolic fraction.

After protein isolation, the concentrations were determined as bicinchoninic (BC) assay as described previously (61) and measuring the absorbance with SpectraFluor Plus™ plate reader. Briefly, 10 µl protein samples were incubated with 200 µl BC assay reagent (30 min at 37 °C) and absorbance was measured (550 nm). As protein standard a dilution series of bovine serum albumin (BSA) was used and sample protein concentration was determined by linear regression. Equal amounts of protein were loaded onto sodium dodecyl sulfate (SDS)-gels, utilizing Page Ruler™ Prestained as a protein ladder indicator. Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE; 20 min: 100 V, 40 min: 200 V) using the Consort Electrophoresis Power Supply E835 and transferred to nitrocellulose membranes (Amersham Bioscience) by tank blotting (1.5 h: 100 V, 4 °C). To block unspecific antibody binding, membranes were incubated with 5 % blotto for 1 h. Primary antibodies were incubated over night at 4 °C and after washing, secondary antibodies were incubated for 2 h at room temperature. Antibodies were diluted in 5 % BSA (Sigma-Aldrich) in TBST. As secondary antibodies were HRP-coupled ECL substrate was added and chemiluminescence was detected with ChemiDoc Touch Imaging System (Bio-Rad Laboratories GmbH). Quantification of bands was accomplished with Image Lab™ Software (Bio-Rad Laboratories GmbH).

Table 8 Buffers for subcellular fractionation

<table>
<thead>
<tr>
<th>Buffer A</th>
<th>Buffer B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>250 mM</td>
</tr>
<tr>
<td>HEPES (pH 7.4)</td>
<td>20 mM</td>
</tr>
<tr>
<td>KCl</td>
<td>10 mM</td>
</tr>
<tr>
<td>MgCl₂</td>
<td>1.5 mM</td>
</tr>
<tr>
<td>EGTA</td>
<td>1 mM</td>
</tr>
<tr>
<td>EDTA</td>
<td>1 mM</td>
</tr>
<tr>
<td>in H₂O</td>
<td></td>
</tr>
</tbody>
</table>

*added before use:*

<table>
<thead>
<tr>
<th>Complete® EDTA free</th>
<th>4 mM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Buffer A</th>
<th>Buffer B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>250 mM</td>
</tr>
<tr>
<td>HEPES (pH 7.4)</td>
<td>20 mM</td>
</tr>
<tr>
<td>KCl</td>
<td>10 mM</td>
</tr>
<tr>
<td>MgCl₂</td>
<td>1.5 mM</td>
</tr>
<tr>
<td>EGTA</td>
<td>1 mM</td>
</tr>
<tr>
<td>EDTA</td>
<td>1 mM</td>
</tr>
<tr>
<td>in H₂O</td>
<td></td>
</tr>
</tbody>
</table>

*added before use:*

<table>
<thead>
<tr>
<th>Complete® EDTA free</th>
<th>4 mM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 9 Buffers for western blot

<table>
<thead>
<tr>
<th><strong>RIPA lysis buffer</strong></th>
<th><strong>5x sample buffer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris/HCl (pH 7.4)</td>
<td>Tris/HCl (pH 6.8)</td>
</tr>
<tr>
<td>NaCl</td>
<td>Glycerol</td>
</tr>
<tr>
<td>Nonidet NP-40</td>
<td>SDS</td>
</tr>
<tr>
<td>Sodium deoxycholate</td>
<td>DTT</td>
</tr>
<tr>
<td>SDS</td>
<td>Pyronin Y</td>
</tr>
<tr>
<td>activated Na&lt;sub&gt;3&lt;/sub&gt;VO&lt;sub&gt;4&lt;/sub&gt;</td>
<td>0.3 mM</td>
</tr>
<tr>
<td>NaF</td>
<td>in H&lt;sub&gt;2&lt;/sub&gt;O</td>
</tr>
<tr>
<td>β-glycerophosphate</td>
<td></td>
</tr>
<tr>
<td>pyrophosphate</td>
<td></td>
</tr>
<tr>
<td>in H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>added before use:</td>
</tr>
<tr>
<td>Complete® EDTA free</td>
<td>Complete® EDTA free</td>
</tr>
<tr>
<td>PMSF</td>
<td>PMSF</td>
</tr>
<tr>
<td>H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;</td>
<td>0.5 mM</td>
</tr>
</tbody>
</table>

**5x sample buffer**

- Tris/HCl (pH 6.8): 3.125 M
- Glycerol: 50 %
- SDS: 5 %
- DTT: 2 %
- Pyronin Y: 0.025 %
- Activated Na<sub>3</sub>VO<sub>4</sub>: 0.3 mM in H<sub>2</sub>O

**1x SDS sample buffer**

- 5x sample buffer: 25 % in H<sub>2</sub>O

### Table 10 Polyacrylamide gels and electrophoresis buffer

<table>
<thead>
<tr>
<th><strong>Stacking gel</strong></th>
<th><strong>Separation gel 10 / 12 %</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rotiphorese&lt;sup&gt;TM&lt;/sup&gt; Gel 30</td>
<td>Rotiphorese&lt;sup&gt;TM&lt;/sup&gt; Gel 30</td>
</tr>
<tr>
<td>Tris (pH 6.8)</td>
<td>Tris (pH 8.8)</td>
</tr>
<tr>
<td>SDS</td>
<td>SDS</td>
</tr>
<tr>
<td>TEMED</td>
<td>TEMED</td>
</tr>
<tr>
<td>APS</td>
<td>APS</td>
</tr>
<tr>
<td>in H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>in H&lt;sub&gt;2&lt;/sub&gt;O</td>
</tr>
</tbody>
</table>

**Electrophoresis buffer**

- Tris: 4.9 mM
- Glycine: 38 mM
- SDS: 0.1 %
- in H<sub>2</sub>O

**Separation gel 10 / 12 %**

- Rotiphorese<sup>TM</sup> Gel 30: 33 / 40 %
- Tris (pH 8.8): 375 mM
- SDS: 0.1 %
- TEMED: 0.1 %
- APS: 0.05 %
- TCE: 0.05 %
- in H<sub>2</sub>O
### Table 11 Tank buffers

<table>
<thead>
<tr>
<th>5x tank buffer</th>
<th>1x tank buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris base</td>
<td>240 mM</td>
</tr>
<tr>
<td>Glycine</td>
<td>195 mM</td>
</tr>
<tr>
<td>in H₂O</td>
<td>20 %</td>
</tr>
<tr>
<td>Methanol</td>
<td>20 %</td>
</tr>
<tr>
<td>in H₂O</td>
<td></td>
</tr>
</tbody>
</table>

### Table 12 ECL solution

<table>
<thead>
<tr>
<th>ECL solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris (pH 8.5)</td>
</tr>
<tr>
<td>Luminol</td>
</tr>
<tr>
<td>p-Coumaric acid</td>
</tr>
<tr>
<td>H₂O₂</td>
</tr>
<tr>
<td>in H₂O</td>
</tr>
</tbody>
</table>

### Table 13 Primary Antibodies for Western Blot

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Company</th>
<th>Cat. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERK 1/2</td>
<td>Cell signaling</td>
<td>9102</td>
</tr>
<tr>
<td>pERK 1/2 Thr202/Tyr204</td>
<td>Cell signaling</td>
<td>9106</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Santa Cruz</td>
<td>sc-69778</td>
</tr>
<tr>
<td>MEK 1/2</td>
<td>Santa Cruz</td>
<td>sc-436</td>
</tr>
<tr>
<td>pMEK 1/2 Ser217/221</td>
<td>Cell signaling</td>
<td>9121</td>
</tr>
<tr>
<td>panRas</td>
<td>Santa Cruz</td>
<td>sc-14022</td>
</tr>
<tr>
<td>Raf 1</td>
<td>Santa Cruz</td>
<td>sc-7267</td>
</tr>
<tr>
<td>pRaf-1 Ser 338 / Tyr 341</td>
<td>Santa Cruz</td>
<td>sc-28005-R</td>
</tr>
<tr>
<td>PI3K</td>
<td>Upstate</td>
<td>06-195</td>
</tr>
<tr>
<td>Akt</td>
<td>Cell Signaling</td>
<td>9272</td>
</tr>
<tr>
<td>pAkt (Ser473)</td>
<td>Santa Cruz</td>
<td>sc-7985-R</td>
</tr>
<tr>
<td>Bad</td>
<td>Cell signaling</td>
<td>9292</td>
</tr>
<tr>
<td>pBad (Ser136)</td>
<td>Cell signanling</td>
<td>9295</td>
</tr>
</tbody>
</table>
Table 14 Secondary Antibodies for Western Blot

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Company</th>
<th>Cat. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse IgG (HRP conjugate)</td>
<td>Santa Cruz</td>
<td>sc-2005</td>
</tr>
<tr>
<td>Rabbit IgG (HRP conjugate)</td>
<td>Bio-Rad</td>
<td>172-1019</td>
</tr>
</tbody>
</table>

2.2.17. Ras activity assay

Ras activation status of the cells was determined using the Ras Assay Kit, according to manufacturer’s protocol. Cells were seeded 24 h prior to treatment with archazolid (2.5/10 nM, 48 h) and cholesterol (10 µg/ml, 48 h). After stimulation, medium was aspirated off, ice-cold lysis solution, containing GST-Raf-RBD which specifically binds to active GTP-bound Ras, was added and cells were scraped off, using a rubber police man. After centrifugation (12,000x g, 4 °C), supernatant was mixed with Glutathione-Sepharose-Slurry beads, that bind to GST-Raf-RBD and incubated under constant mixing for 30 min at 4 °C. After incubation, beads were spun down and drained well, mixed with SDS-containing sample buffer for SDS-PAGE, denatured for 10 min at 95 °C and subjected to Western Blot as described in paragraph 2.2.16. Protein loading on the gel was determined using 0.5 % trichloroethanol (Sigma) polyacrylamide gels as described before (62). Primary antibody detecting panRas was provided in the kit and secondary antibody goat-anti-mouse IgG conjugated to HRP were used (Santa Cruz).

2.2.18. Quantitative real-time PCR (qPCR)

Cells were treated as indicated and total mRNA was isolated using the Qiagen RNeasy Mini Kit according to manufacturer’s protocol. The concentration of isolated messenger RNA (mRNA) was determined using the NanoDrop® ND-1000 spectrophotometer analyzing the absorption at 260 nm (A260) and 280 nm (A280). The obtained RNA was re-transcribed using the High Capacity cDNA Reverse Transcription Kit according to manufacturer’s instructions. Obtained complementary DNA (cDNA) was stored at 4 °C until quantitative real-time Polymerase Chain Reaction (qPCR). The SYBR Green Master Mix was used with the respective primers. Actin served as housekeeping gene. qPCR was performed with the QuantStudio® 3 Real-Time Instrument. Average CT values of target genes were normalized to control as ΔCT. Changes in mRNA expression levels were shown as
fold expression \( (2^{\Delta\Delta CT}) \) calculated by the \( \Delta\Delta CT \) method normalized to housekeeping gene as described previously (63).

**Table 15 Primer sequences used for qPCR**

<table>
<thead>
<tr>
<th>target mRNA</th>
<th>forward sequence</th>
<th>reverse sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>actin</td>
<td>5' CCA ACC GCG AGA AGA TGA 3'</td>
<td>5' CCA GAG GCG TAC AGG GAT AG 3'</td>
</tr>
<tr>
<td>LDL-R</td>
<td>5' CTA CAA GTG GGT CTG CGA TG 3'</td>
<td>5' TTT GCA GGT GAC AGA CAA GC 3'</td>
</tr>
<tr>
<td>LX-R</td>
<td>5' TTC ACC TAC AGC AAG GAC GA 3'</td>
<td>5' GAA CTC GAA GAT GGG GTT GA 3'</td>
</tr>
<tr>
<td>HMGCR</td>
<td>5' GTC ATT CCA GCC AAG GTT GT 3'</td>
<td>5' GGG ACC ACT TGC TTC CAT TA 3'</td>
</tr>
<tr>
<td>SREBP-2</td>
<td>5' ACA AGT CTG GCG TTC TGA GG 3'</td>
<td>5' ACC AGA CTG CCT AGG TCG AT 3'</td>
</tr>
</tbody>
</table>

2.2.19. *In vivo* HUH-7 xenograft mouse model

Thirty-two female SCID mice (Charles River „CB17/Scid-PrkdcScid/Scid/cr”) were locally shaved and 3x10^6 HUH-7 cells were injected subcutaneously into the flank of each mouse. Mice were divided into four groups and treated intraperitoneally with 0.2 mg/kg archazolid, 10 mg/kg simvastatin, 0.2 mg/kg archazolid in combination with 10 mg/kg simvastatin in 5% DMSO / 10% solutol / PBS or equal amounts of 5% DMSO / 10% solutol / PBS. Mice were treated daily. Measurement of tumors was done every 2 to 3 days with a caliper, using the formula a x b2/2. The average tumor volumes of the two groups were compared over time. *In vivo* experiments were executed by Melanie Ulrich and Kerstin Loske (Group of Prof. Dr. Angelika M. Vollmar, University of Munich, Pharmaceutical Biology). Animal experiments were approved by the District Government of Upper Bavaria in accordance with the German animal welfare and institutional guidelines.

2.2.20. Immune histochemistry (IHC)

IHC analysis of tumor tissue sections was performed as described previously [49] using anti-LAMP1-antibody (Abcam), filipin (Sigma Aldrich), anti-Ki67-antibody and haematoxylin (Sigma Aldrich).
For Ki67 staining, paraffin embedded tumor sections were de-paraffinized by incubation in xylol, followed by ethanol 100 %, ethanol 95 % and water. For antigen retrieval, tissue sections were incubated in sodium citrate buffer at 95 °C for 20 min. After cooling, sections were washed two times with 0.05 % triton-X in PBS, peroxidase activity was quenched with 7.5 % H₂O₂ in water for 10 min at room temperature and unspecific binding was blocked with blocking serum of the VECTASTAIN Elite ABC HRP Kit for 20 min at room temperature. Sections were incubated with anti-Ki67-antibody (ab-15580, abcam) for 1 h at room temperature, washed twice with PBS, incubated with secondary antibodies and universal reagent of the VECTASTAIN Elite ABC HRP Kit. After washing, AEC substrate from the ImmPACT AEC Peroxidase (HRP) Substrate kit was added for 30 min. After additional washing, haematoxilin counterstaining was performed, sections were washed and mounted in FluorSafe™ and sealed with cover slides. Ki67 staining was evaluated using the Olympus BX41 microscope.

For LAMP-1 and cholesterol staining the same procedure was used, however, secondary antibody mouse IgG (AlexaFluor 488 conjugate) and filipin were added in blocking solution of the VECTASTAIN elite ABC HRP Kit for 2 h at room temperature. Cholesterol and LAMP-1 staining were evaluated by confocal microscopy using a Leica TCS SP 8 SMD confocal microscope.

Table 16 Buffer for IHC

<table>
<thead>
<tr>
<th>Sodium citrate buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tri-Na-Citrate(dihydrate)</td>
</tr>
<tr>
<td>Tween</td>
</tr>
<tr>
<td>HCl ad pH 6.0</td>
</tr>
</tbody>
</table>

| in H₂O                      |

2.2.21. Statistical Analysis

All experiments were performed at least three times unless stated otherwise. Statistical analysis was performed using GraphPad Prism® (GraphPad Software, Inc., La Jolla, CA, USA). Graph data represent means ± SEM. One-way ANOVA/Dunnett’s multiple comparison test and individual unpaired t-tests were conducted. p values less than 0.05 were considered significant.
3. RESULTS

3.1. V-ATPase inhibition induces cancer cell stiffening and alters membrane fluidity in HCC

3.1.1. Real-time deformability cytometry reveals cancer cell stiffening due to V-ATPase inhibition

Biophysical characteristics of cancer cells have come into focus lately, regarding the search for new therapy options. In this context, it has been reported that increased softness of cancer cells correlates with malignancy (46). Interestingly, the V-ATPase has been reported to regulate cholesterol metabolism (10,11,23), a fact which lead to the working hypothesis that inhibition of V-ATPase by archazolid A might influence cancer cell biophysical properties. To elucidate this hypothesis, we utilized a relatively new method to analyze the deformation of cells, the real-time deformability cytometry (RT-DC) in collaboration with Dr. Maria Winzi (Group of Prof. Dr. Jochen Guck, Biotec, TU Dresden). RT-DC is a microfluidic-based technique which allows the measurement of cell deformation while cells pass through a narrow constriction with a rate of 100 cells/s (59).

We analyzed the influence of archazolid A treatment on the deformability of HUH-7 cancer cells and the non-malignant hepatocyte-like cell line HepaRG. Firstly, we assessed the influence of the applied flow rates on the deformation, as they correlate with shear force subjected to the cells. We found that at all applied flow rates, HUH-7 cells behaved similarly (Fig 14 A). In general, we could show that HUH-7 control cells change their shape to a rather oval structure, whereas treated HUH-7 cells remain quite spherical (Fig 14 C). Secondly, we also monitored the behavior of HepaRG cells at different flow rates and revealed that also for the non-malignant cells, effects are independently of the force applied (Fig 14 B). To exclude that cellular shape is altered directly by stimulation, cells were imaged in the reservoir before entering the channel, however, no difference was detected (Fig 14 A, B). Taken together, the RT-DC measurements clearly showed that treatment reduces overall deformability of HUH-7 cells (Fig 14 D), whereas deformability of HepaRG remained unaffected (Fig 14 E), indicating a cancer cell selectivity of the effect.
Figure 14 V-ATPase inhibition selectively reduces deformability of cancer cells in RT-DC measurements. HUH-7 (A) and HepaRG (B) cells were left untreated (blue) or were treated with archazolid A (10 nM, 24 h) (red) and subjected to flow rates of 0.16 µl/s, 0.24 µl/s or 0.32 µl/s or no shear stress (reservoir). Blots show contours of dot blots of deformation compared to cell size. (C) Representative images of an HUH-7 control cell (upper image) and an archazolid A (10 nM, 24 h) treated cell (lower image) when subjected to shear force in the flow channel (0.24 µl/s). Red line indicates outline for calculation of deformation. (D, E) Representative dot blots of deformation compared to cell size at a flow rate of 0.16 µl/s for HUH-7 and HepaRG, respectively. Blue dots represent control cells, red dots represent archazolid A treatment (10 nM, 24 h). Graphs represent cell size (cross sectional area) versus deformation (1-circularity) with isoelasticity lines representing areas of identical stiffness. p*< 0.01, p-values of three independent experiments with > 3000 cells per experiment were determined by a likelihood ratio test.
3.1.2. V-ATPase inhibition induced cell stiffening due to alterations in membrane properties

The stiffness of cells in general is mainly influenced by two factors: the cytoskeleton and the membrane. As we could detect no evident differences in actin cytoskeleton of HUH-7 cells (Fig 15), we focused on possible effects of archazolid A treatment on the membrane.

![Figure 15 V-ATPase inhibition shows no evident influence on actin cytoskeleton](image)

HUH-7 cells were treated with archazolid A as indicated (24 h) stained for actin (red) and nuclei (blue) and analyzed by confocal microscopy. Representative images out of three independent experiments are shown. Scale bar 25 µm.

For this purpose, we analyzed plasma membrane fluidity, using a fluorescence-recovery after photo-bleaching (FRAP) approach on cells transfected with a membrane-targeted (i.e. farnesylated) GFP coding plasmid. After bleaching fluorescence in a specific membrane area, recovery was monitored over time and the speed constant was calculated as described in the methods section (2.2.10). In control cells, the bleached area was repaired relatively fast, whereas in archazolid A treated cells the restoration of fluorescence was hindered (Fig 16 A). Hence, the recovery constant was significantly slower in treated cells compared to control cells (Fig 16 B). This finding indicates reduced lateral mobility of farnesylated proteins in the plasma membrane of archazolid A treated cells.
RESULTS

Figure 16 V-ATPase inhibition causes alterations in membrane fluidity (A, B) FRAP of HUH-7 cells transfected with membrane targeted (farnesylated) GFP and treated with archazolid A (10 nM, 24 h) was analyzed by confocal microscopy. Recovery speed constant K was calculated by non-linear curve fit. One representative image and diagram of FRAP recovery of three independent experiments are shown. Bars are the mean ± SEM of three independent experiments. p*<0.05 One-way ANOVA, Dunnett post test

The plasma membrane of mammalian cells is composed of a variety of different lipids and proteins, which influence membrane biophysical properties, localization of signaling molecules and fluidity (64). In order to investigate the cause of the reduced lateral mobility of farnesylated proteins, we investigated specifically polarity of the membrane. Therefore, we used the membrane-intercalating, polarity sensitive dye di-4-ANEPPDHQ. This dye undergoes a 60 nm spectral blue shift between disordered and ordered membrane compartments, representing non-raft and cholesterol-rich lipid-raft membrane regions, respectively. These special fluorescent properties of di-4-ANEPPDHQ allow a quantitative analysis of membrane polarity, by calculating a value for generalized polarization (GP), as described previously (65).

Treatment with archazolid A resulted in a drop of GP values, indicating an increase in membrane polarity in HUH-7 and HepG2 cells. In contrast, the non-malignant HepaRG cells and primary human hepatocytes (hHep) showed no change in membrane polarity following treatment. (Fig 17 A). For easy visualization, heat map images (Fig. 17 C) and GP value distribution histograms (Fig. 17 D) were compiled. To exclude responsibility of an off-target event for increased membrane polarity, we performed siRNA mediated knock-down of the V-ATPase and subsequently
measured GP values. Knocking-down V-ATPase also reduced GP values, confirming V-ATPase dependency of the mechanism (Fig 17 B). These results clearly depict the ability of archazolid A to alter biophysical characteristics selectively in cancer cells, while leaving non-malignant cells unaffected.

Figure 17 V-ATPase inhibition leads to an alteration in plasma membrane composition
(A) HUH-7, HepG2, HepaRG and hHep were treated with archazolid A as indicated (2.5/10 nM, 24 h) and (B) HUH-7 cells were transiently transfected with nt siRNA or siRNA silencing c-subunit of the V-ATPase (ATP6V0C siRNA) (72 h). Membrane polarity was analyzed by confocal microscopy of live cells stained with di-4-ANEPPDHQ. Representative heat map images (C) and histogram (D) of generalized polarization (GP) value distribution of HUH-7 di-4-ANEPPDHQ stainings are shown. A GP value drop indicates increased membrane polarity. Bars are the mean ± SEM of three independent experiments. p*<0.05 One-way ANOVA, Dunnett post test (A) or unpaired t-test (B)
3.2. **V-ATPase inhibition alters cholesterol metabolism of HCC cells**

We could show that archazolid A alters plasma membrane properties of cancer cells. The plasma membrane of eukaryotic cells is composed of phospholipids, sphingolipids and the rather unpolar sterol cholesterol (66). In order to determine the cause for reduced fluidity and increased membrane polarity, we focused on analyzing membrane components.

### 3.2.1. Availability of free cholesterol is diminished upon V-ATPase inhibition

We focused on cholesterol metabolism, as it has been reported recently to be influenced by the V-ATPase (10). Employing the enzyme-based Amplex Red® cholesterol measurement kit, we evaluated levels of both, total and free cholesterol. The assay revealed, that treatment with archazolid A led to a reduction in the proportion of free cholesterol in HCC cell lines, yet leaving non-malignant cells unaffected (Fig 18 A). In HUH-7 cells, knock-down of the V-ATPase also reduced the proportion of free cholesterol within the cell, ensuring a V-ATPase dependent mechanism (Fig 18 B).

Additionally, we conducted ultraperformance liquid chromatography-coupled ESI tandem mass spectrometry (UPLC-MS/MS) measurements in cooperation with Dr. Andreas Koeberle (Group of Prof. Oliver Werz, Institute of Pharmacy, Friedrich Schiller University Jena). UPLC-MS/MS analysis of cholesteryl-ester (CE) species in archazolid A treated HUH-7 cells showed, that while the overall amount of CE within the cells is not altered (Fig 18 C), the composition of CE changes upon V-ATPase inhibition (Fig 18 D). These data point to a role of V-ATPase in the availability of free cholesterol and CE composition.
RESULTS

Figure 18 V-ATPase inhibition reduces free cholesterol levels and alters cholesteryl-ester composition (A) Ratio of levels of free to total cholesterol of HUH-7, HepG2, HepaRG and hHep cells treated with archazolid A (2.5/10 nM, 48 h) assessed by Amplex Red® assay. (B) HUH-7 cells were transiently transfected with nt siRNA or siRNA silencing c-subunit of the V-ATPase (ATP6V0C siRNA) (72 h) and cholesterol content was analyzed. (C, D) HUH-7 cells were treated with archazolid A (2.5/10 nM, 48 h), lipids were extracted and CE composition was analyzed by mass spectrometry. Bars are the mean ± SEM of three independent experiments. p*<0.05 One-way ANOVA, Dunnett post test (A, C, D) or unpaired t-test (B).

3.2.2. V-ATPase inhibition impedes internalization of LDL via the LDLR and enhances LDLR expression

Free cholesterol availability in mammalian cells is dependent on supply by de novo synthesis or by uptake of cholesterol as main component of low-density lipoprotein (LDL) via its respective receptor (LDLR), however uptake by internalization is the primary cholesterol source. In previous studies of our group, we showed an inhibition of EGF and transferrin receptor recycling by archazolid (11,23), hence we hypothesized a similar fate for the LDLR.

Therefore, we analyzed the presence of the LDLR on the surface of HUH-7 cells. Flow cytometry with labelled antibody conjugates revealed an increased amount of the LDLR on the surface of archazolid A treated HUH-7 cells (Fig 19 A). Enhanced
surface appearance can be caused by several ways in principle, on the one hand by increased expression of the protein and on the other hand by reduced internalization. In order to investigate the underlying mechanism we analyzed LDLR expression level upon archazolid A treatment by quantitative real-time PCR (qPCR). The experiment revealed increased expression of the receptor on mRNA level upon inhibition of the V-ATPase (Fig 19 B).

So as to investigate the effect of archazolid A on LDLR internalization, we used two different strategies. Firstly, we performed an LDLR internalization assay with a fluorescently labelled antibody conjugate (Fig 19 C). After internalization, LDLR distribution within the cell was visualized by confocal microscopy. In control cells, LDLR is properly internalized, leading to intracellular bright green dots in the confocal image (Fig 19 C, upper lane). Following archazolid A treatment, the green signal disappears leaving only diffuse membrane staining (Fig 19 C, lower lane), pointing to a reduction in internalization. In a second approach, we used a labelled LDL conjugate (Fig 19 D). In a similar internalization assay, we could show that LDL is properly internalized in control cells (Fig 19 D, upper lane), but internalization is diminished by archazolid A treatment, leading to accumulation of LDL at the outer boarder of the cells (Fig 19 D, lower panel).

Taken together, these findings clearly show that treatment with archazolid A leads to increased LDLR transcription and a decreased LDLR internalization, followed by a decreased uptake of LDL together with an increased presence of LDLR on the cellular surface, thereby most likely disturbing cholesterol metabolism.
**Figure 19 LDLR internalization and LDL uptake is inhibited by archazolid A treatment**

(A) LDLR surface expression of HUH-7 cells was visualized by antibody staining and analyzed by flow cytometry after archazolid A treatment (2.5/10 nM, 24 h). (B) Relative mRNA expression levels of LDLR in HUH-7 cells were detected with the AB 7300 RealTime PCR system. Bars are the mean ± SEM of three independent experiments. *p*<0.05 Repeated measures ANOVA, Dunnett post test. (C) HUH-7 cells were treated with archazolid A (2.5/10 nM, 24 h) and subsequently starved for 2 h. After incubation with PMA (1 h) internalized LDLR was visualized by antibody staining and analyzed by confocal microscopy. (D) HUH-7 cells were treated with archazolid A (2.5/10 nM, 24 h) and subsequently starved for 1.5 h. Internalization of DilLDL (fluorescently labeled soluble LDL) was analyzed by confocal microscopy. Representative images out of three independent experiments are shown. Scale bar 25 µm (left columns) and 5 µm (right columns), respectively.
3.2.3. V-ATPase inhibition leads to cholesterol trapping and induction of *de novo* synthesis

In summary, our previous data show a restriction of free cholesterol, plasma membrane cholesterol depletion and a reduction of LDL uptake, however, the question where the free cholesterol is located still remained. In order to clarify this issue, we investigated subcellular localization of cholesterol. As free cholesterol is mainly released from lysosomes under normal conditions and lysosomes greatly depend on a functional V-ATPase, we assumed lysosomes as location for the restricted cholesterol in archazolid A treated cells.

We hence isolated lysosomes from treated cells as described previously (56), and measured cholesterol levels employing the Amplex Red® cholesterol measurement kit. The analysis showed, that the amount of cholesterol in purified lysosomes drastically increases due to archazolid A treatment (Fig 20 A). This finding could further be supported by a confocal staining for cholesterol and the lysosomal marker protein LAMP-1. Control cells displayed a fine dispersion of LAMP-1 and cholesterol within the cell, whereas archazolid A treated cells showed huge accumulations of colocalized stainings (Fig 20 B), indicating a cholesterol trapping within the lysosomes of treated cells.

Since archazolid A treated cells obviously suffer from cholesterol depletion, due to trapping in the lysosomes and impaired uptake, we supposed that the cells might upregulate *de novo* cholesterol synthesis. We therefore investigated the impact on cholesterol regulating genes SREBP-2 and HMGCR of archazolid A single treatment and combination treatment of archazolid A with the cholesterol synthesis inhibitor simvastatin to block possibly increased synthesis. qPCR analysis showed, that cells indeed upregulate the expression of SREBP-2 (Fig 20 C), the master regulator of cholesterol synthesis and also the expression of HMGCR (Fig 20 D). HMGCR is the direct target of simvastatin and catalyzes the reduction of HMG-CoA to mevalonate, the rate-limiting step of cholesterol synthesis. As expected, combination therapy further enhanced archazolid A induced upregulation of transcription, indicating a feedback regulation, due to cholesterol depletion.
Figure 20 Lysosomal cholesterol trapping and induction of de novo cholesterol synthesis due to archazolid A treatment (A) HUH-7 cells were treated with archazolid A as indicated (2.5/10 nM, 48 h) and lysosomes were isolated. Levels of total cholesterol in lysosomes were analyzed by AmplexRed® assay. (B) HUH-7 cells were treated as indicated (2.5/10 nM, 24 h), stained for cholesterol (red), lysosomes (green) and nuclei (blue) and analyzed by confocal microscopy. Representative images out of three independent experiments are shown. Scale bar 20 µm. (C, D) HUH-7 cells were treated as indicated with archazolid A, simvastatin or a combination of both compounds as indicated for 24 h. Relative mRNA expression levels of SREBP-2 and HMGCR respectively, were detected with the AB 7300 RealTime PCR system. Bars are the mean ± SEM of three independent experiments. p*<0.05 Repeated measures ANOVA, Dunnett post test
3.3. **Plasma membrane cholesterol depletion leads to impaired Ras signaling**

3.3.1. **Activation of the small GTPase Ras is impaired upon V-ATPase inhibition**

As cholesterol homeostasis is disrupted due to lysosomal trapping leading to plasma membrane cholesterol depletion, we were interested in possible functional consequences. Cholesterol-rich lipid-rafts are particularly important signaling platforms for the activation of farnesylated proteins (52), so we investigated the impact of archazolid A treatment on the small GTPase Ras. First of all, we checked for changes in the overall protein level of Ras, yet could not determine any changes following treatment (Fig 21 A). In a second approach, we performed a subcellular fractionation to obtain the membrane fraction of the cells, in which we quantified Ras protein expression. We could observe a significant reduction of Ras protein levels within membrane fractions (Fig 21 B) and furthermore, confocal staining of Ras showed that while the signal is finely dispersed over the whole cell in control cells, the Ras staining is restricted to few accumulations in archazolid A treated cells (Fig 21 C). These findings point to a mislocalized Ras protein, leading to the assumption that Ras activation might be hindered.

To test this hypothesis, we precipitated active Ras in whole cell lysates of treated and control cells and found that the amount is decreased upon archazolid A treatment (Fig 21 D). To proof that inhibition of Ras activation is cancer cell specific, we induced Ras signaling in the non-malignant HepaRG cells by EGF treatment and then observed the effect of archazolid A on active Ras. The fact that we could not observe changes in active Ras levels in HepaRG cells (Fig 21 E) indeed points to a tumor specific effect. To verify plasma membrane cholesterol depletion as underlying mechanism of decreased Ras activation, we added soluble cholesterol to the medium of treated cells and quantified Ras activation. Ras remained active despite archazolid A treatment when medium was supplemented with cholesterol (Fig. 21 F) confirming a cholesterol dependency.
**RESULTS**

Figure 21 Archazolid A reduces Ras activation in a cholesterol-dependent manner (A) PanRas protein expression of HUH-7 cells was detected by western blot (WB) upon archazolid A treatment (48 h). (B) PanRas protein level in membrane fractions of archazolid A (48 h) treated HUH-7 was detected by WB. (C) HUH-7 cells were treated as indicated (2.5/10 nM, 24 h), stained for cholesterol (blue), panRas (green) and nuclei (red) and analyzed by confocal microscopy. White arrow heads show Ras accumulations. Representative images out of three independent experiments are shown. Scale bar 20 µm. (D, E) Active Ras was precipitated in cell lysates of archazolid A treated (48 h) HUH-7 and HepaRG cell lysates and analyzed by WB, respectively. In HepaRG cells Ras signaling was stimulated by EGF (100 ng/ml) treatment 15 min prior to lysis. (F) HUH-7 cells were treated with archazolid A together with or without cholesterol as indicated (48 h). Active Ras was precipitated in cell lysates and detected by WB. Bars are the mean ± SEM of three independent experiments. p*<0.05 One-way ANOVA, Dunnett post test.
3.3.2. Ras downstream signaling is altered upon treatment

Signaling of the small GTPase Ras is of crucial importance for various downstream signaling pathways within the cell. Most prominent are the MAPK pathway and the PI3K/Akt pathway (52). In order to examine possible effects on downstream signaling, we performed western blot experiment on various different downstream regulators.

Our data show that the activating phosphorylation of Raf-1, MEK 1/2 and ERK 1/2 is reduced upon archazolid A treatment (Fig 22 A), indicating an inhibition of the MAPK pathway, whereas PI3K/Akt remains unaffected (Fig 22 B). To compensate a possible escape mechanism by increased cholesterol synthesis, we additionally treated cells with simvastatin. Simvastatin treatment alone did not affect MAPK or PI3K/Akt signaling and combination therapy showed similar effects as archazolid A single treatment (Fig 22 A, B).

In these experiments we could show that archazolid A reduces MAPK signaling downstream of Ras activation.

**Figure 22 Effect of archazolid A on Ras downstream signaling** Protein expression of Raf-1, pRaf-1 (Ser338/Tyr341), MEK 1/2, pMEK 1/2 (Ser217/221), ERK 1/2 and pERK 1/2 (Thr202/Tyr204) (A) or PI3K, Akt, pAkt (Ser473), Bad and pBad (Ser136) (B) of HUH-7 cells treated with archazolid A, simvastatin or combination (48 h) was analyzed by WB. GAPDH served as loading control.
3.4. A combination therapy approach to inhibit HCC proliferation

3.4.1. A combination of archazolid and simvastatin leads to synergistic growth inhibition of HCC cells *in vitro*

We showed that archazolid A is able to restrict cholesterol access and to cause inhibition in MAPK signaling due to cholesterol depletion in a Ras dependent manner. As Ras signaling is essential for cancer cell proliferation we investigated the influence of archazolid A in a CellTiter Blue proliferation assay. Treatment of the cancer cell lines HUH-7 and HepG2 resulted in a strong, concentration dependent inhibition of proliferation, while HepaRG cells remained unaffected (Fig 23 A) supporting the previously detected cancer cell specificity.

As we had observed an upregulation of cholesterol synthesis regulating genes SREBP-2 and HMGCR (see Fig 20 C, D), we assumed that a combination therapy of archazolid A with the HMGCR inhibitor simvastatin might be beneficial for treatment, despite the fact that simvastatin treatment did not significantly affect Ras downstream signaling (see Fig 21 A, B). Firstly, we analyzed the ability of simvastatin single treatment on the proliferation of HCC cells. A CellTiter Blue assay revealed that simvastatin single treatment concentration dependently reduced the ability of HCC cells to proliferate (Fig 23 B). In a second approach we investigated the beneficial effect on proliferation of a combination therapy with both drugs. We could show that the combination therapy synergistically inhibits proliferation of HUH-7 and HepG2 cells *in vitro* (Fig 23 C).

The MAPK pathway is known to be important in the regulation of proliferation. However, induction of apoptosis might also be responsible for the reduced viability of HCC cells in the CTB assay. To address this question, we determined apoptosis and found that apoptosis is almost at control level in single treatment and only mildly increased in combination therapy (Fig 23 D), indicating inhibition of proliferation as main mechanism of action. In addition, we could show that combination therapy also has a long-term inhibiting effect on proliferation, as determined by clonogenic survival assay (Fig 23 E).

In conclusion, our data show a strong anti-proliferative effect of archazolid A on HCC cells and a clearly beneficial effect of combining archazolid A with simvastatin *in vitro*. 
Figure 23 Combination therapy with archazolid A and simvastatin shows strong anti-proliferative effects (A) Proliferation of HUH-7, HepG2 and HepaRG cells was analyzed in a CellTiter Blue assay, after treatment as indicated with archazolid A (72 h). (B, C) Proliferation of HUH-7 and HepG2 was analyzed in a CellTiter Blue assay after treatment with simvastatin or combination therapy as indicated (72 h), respectively. (D) Apoptotic cell death of HUH-7 and HepG2 cells treated as indicated (48 h) was analyzed by PI staining and subsequent flow cytometry. (E) HUH-7 cells were pre-treated as indicated for 24 h and subjected to clonogenic survival for 7 d. Colonies were stained with crystal violet and imaged at 10x magnification. Crystal violet was re-dissolved and staining was assessed by measurement of absorption. Bars are the mean ± SEM of quantification of three independent experiments. p*<0.05 One-way ANOVA, Dunnett post test
3.4.2. Archazolid strongly inhibits tumor growth in an *in vivo* mouse xenograft model

Following the quite promising effects of a combination therapy on *in vitro* proliferation, we performed a HUH-7 mouse xenograft model. Importantly, daily treatment of mice bearing solid tumors with archazolid for 10 days resulted in a significant decrease in tumor size at study endpoint (Fig 24 A, red bar). Also the respective growth rate of tumors in archazolid treated mice was significantly slower than in control group (Fig 24 B, red curve). Surprisingly, treatment of mice with simvastatin lead to slightly increased tumor volume at study end point (Fig 24 A, yellow bar) and an increased proliferation rate (Fig 24 B, yellow curve). This resulted in a tumor volume comparable to control cells, and only a slightly reduced proliferation rate of tumors in animals treated with a combination therapy (Fig A and B, orange bar and curve).

Since the liver is the primary organ in regulating cholesterol homeostasis *in vivo*, livers were dissected at study endpoint to check for obvious side effects of treatment. Visual examination of the livers showed no obvious signs for severe side effects like e.g. fatty livers (Fig 24 C).

Consistent with the reduction in proliferation rate and reduced tumor volume upon archazolid treatment, expression of the proliferation marker Ki67 was significantly reduced in tissue samples of tumor sections (Fig 24 D). Furthermore, staining of tumor sections for cholesterol and lysosomes revealed lysosomal accumulation as expected by our *in vitro* data.

Taken together, we could show that archazolid strongly inhibits proliferation of HCC cells *in vitro* and *in vivo* by cholesterol restriction to the lysosomes. However, a combination therapy of archazolid and simvastatin *in vivo* needs further evaluation.
Archazolid leads to reduced proliferation \textit{in vivo} (A, B) HUH-7 cells were injected s.c. into the flanks of 32 SCID mice. Mice were divided in four groups and treated daily i.p. with archazolid, simvastatin, a combination thereof or equal amounts of solvent. Tumor volume (A) and growth rates $\alpha$ (B) (Co $\alpha = 1.374 \text{ mm}^3/\text{h}$, archazolid $\alpha = 0.733 \text{ mm}^3/\text{h}$, simvastatin $\alpha = 1.687 \text{ mm}^3/\text{h}$, combination $\alpha = 1.119 \text{ mm}^3/\text{h}$) are indicated. (C) At study end point mice were sacrificed and livers were dissected for visual examination. (D) Paraffin sections of tumors were stained for Ki67 and nuclei. (E) Paraffin sections of tumors were stained for cholesterol (blue) and LAMP-1 (green). Representative images of control and archazolid treated mice are shown. Scale bar 20 $\mu$m. Bars are the mean $\pm$ SEM of three independent experiments. $p^*<0.05$ One-way ANOVA, Dunnett post test (A, B) or unpaired t-test (D), respectively.
DISCUSSION
4. DISCUSSION

This work reveals that the V-ATPase inhibitor archazolid reduces tumor cell proliferation in vitro and in vivo by modifying the mechanical phenotype of HCC cells through lysosomal cholesterol trapping, while leaving non-malignant cells unaffected. In an interdisciplinary approach using biophysical and cell-biological methods we were able to identify a new option for the treatment of HCC. Furthermore, we found evidence, that a combination therapy of V-ATPase inhibition with cholesterol synthesis inhibitors might be beneficial.

4.1. The V-ATPase influences membrane properties of the cell - and vice versa?

In the recent past, research mainly focused on directly influencing signaling pathways in order to affect proliferation, invasion and metastasis of cancer cells. Lately however, evidence accumulates that these processes greatly depend on the biomechanical and biophysical aspects of the cells and their environment (67), which opens new possibilities in cancer treatment.

In our study, we show that the HCC cell line HUH-7 is more deformable than the non-malignant hepatocyte cell line HepaRG, indicating increased compliance as a characteristic of liver cancer. These data are in line with the findings of Zhang et al., which reveal differences in elastic coefficients of HCC cells compared to non-malignant tissue and connect them to tumor cell invasion and metastasis (68). Indeed, several studies now exist, which analyzed differences in mechanical phenotype of cancer cells in comparison to their non-malignant counterparts. Along this line, Lin et al. found that different cell lines of breast, bladder, cervical and pancreatic cancer show increased softness when compared to their respective, non-malignant counter-parts. Furthermore, they correlated increased migratory and invasive capability with a loss of sensing and adaption to stiffness changes of the extracellular environment (46). Another study showed a correlation of the softness of tumor cell lines and patient cancer cells with invasiveness and even postulates the use of the mechanical phenotype for grading (69). Moreover, our data show that pharmacological V-ATPase inhibition in HCC cell lines increased cell stiffness compared to untreated cells, while leaving non-malignant cells unaffected, thereby
opening a new possibility for the treatment of HCC by specifically addressing biomechanical properties of liver cancer cells.

We could demonstrate that this effect was due to plasma membrane cholesterol depletion and most likely subsequent disruption of lipid-rafts. Yet, the existence of a loop regulation in this regard is possible, in which the activity of the V-ATPase is further decreased by disruption of lipid-rafts. It has been shown by proteomic analysis, that several subunits of the V-ATPase are depleted from lipid-rafts by cholesterol-disrupting drugs, indicating a raft localization of the proton pump (70). A study by Lafourcade et al. showed that the membrane-integral V-ATPase subunits were associated with detergent resistant membranes, i.e. lipid-raft like domains, isolated from late endosomes. They could show that inducing cholesterol accumulation in late endosomes affected acidification, thereby raising the possibility that association with lipid-raft regulates V-ATPase activity. (71) Another study identified V-ATPase subunits in flotillin 1 enriched triton-insoluble domains of monocytes that can be thought of as lipid-rafts (72). Since it has also been reported, that the activity of the Na⁺/K⁺-ATPase is influenced by membrane cholesterol levels (73), one may hypothesize that the disruption of lipid-rafts by cholesterol depletion caused by V-ATPase inhibition in turn further decreases activity of the proton pump in the fashion of a positive feedback loop. However, the available data are scarce and further studies specifically addressing this matter are needed.

Biophysical properties of the cell are greatly determined by the status of the cytoskeleton, which has been thoroughly studied yet remains unaffected in our study, but also by the plasma membrane composition, of which less is known (74-76). Investigating the membrane properties remains challenging, owing to the complex nature of their composition. Thousands of different lipid species build the backbone of cellular membranes and only due to advances in chromatographic, mass spectrometric and imaging techniques lipid bilayers can now be investigated in more detail. However, satisfying in vitro modification options for the plasma membrane composition are still largely missing (64) hence complicating functional membrane studies.
4.2. **Cholesterol - an essential factor in cancer cell survival**

Cholesterol is a major component of the plasma membrane essentially regulating membrane fluidity, vesicle trafficking, endocytosis and receptor signaling. It has been reported, that cholesterol is crucial for the cytoskeletal adhesion to the plasma membrane in endothelial cells, thereby substantially regulating cell morphology and stiffness - properties that can be influenced by cholesterol depletion (77). In terms of cancer, studies revealed that lipid metabolism is deregulated in different cancers and that aberrant cholesterol metabolism in HCC seems to be a crucial factor in the malignant phenotype (45,66,78,79). In the present study, we could reveal that archazolid selectively reduces free cholesterol levels in HCC cell lines, but not in non-malignant hepatocytes, reinforcing increased compliance and altered lipid metabolism as druggable characteristics of cancer cells in general.

However, the mechanism of cholesterol reprogramming in cancer and subsequent effects still need to be fully examined (48). A study on primary tumor cells and HCC cell lines for instance showed that elevations in overall or mitochondrial cholesterol content were correlated with increased expression of the mitochondrial cholesterol–transporting polypeptide steroidogenic acute regulatory protein (StAR) and chemotherapy resistance together with protection from apoptosis (42). Others reported, that increased mitochondrial cholesterol content due to mutations in the cholesterol export gene ABAC1 also reduced sensitivity to apoptotic signals (80), while contradictory results implicated STARD3, a lipid transfer protein, with poor prognosis in breast cancer (81). Of note, archazolid has been shown by our group to selectively induce apoptosis in tumor cells via induction of intrinsic apoptosis and cellular stress response (12). In context with the relevance of cholesterol for mitochondria, cellular cholesterol depletion as reported in this study might support induction of apoptosis by archazolid.

Cholesterol homeostasis is tightly regulated in cells, by means of synthesis, esterification, metabolism, influx end efflux (34,81,82). The key regulator, that increases cellular cholesterol content is the transcription factor sterol-regulatory element binding protein 2 (SREBP-2), which leads to increased de novo synthesis as well as uptake of cholesterol containing lipoproteins and decreased efflux (81). Upon cholesterol depletion sensed by the ER membrane, SREBP-2 is transported to the Golgi for cleavage and subsequently its n-terminal, active form is translocated to the nucleus, where it induces transcription of HMGCR, LDLR and many other genes (34).
Recently, Hamm et al. connected archazolid treatment to an induction of cholesterol metabolism, stating that this is a main resistance mechanism of bladder cancer cells to the treatment (10). In accordance with their data, we found transcriptional induction of SREBP-2, HMGCR and LDLR. However, we draw different conclusions. For one, cholesterol is trapped in the lysosomes leading to depletion of the membrane and thereby alteration of biophysical characteristics and proliferative signaling, which we think is part of the drugs mechanism of action. Additionally, as we show that archazolid blocks LDLR internalization, upregulation of the protein should therefore have no functional consequences. For another, the feedback upregulation of cholesterol synthesis opens the possibility for a combination therapy with statins as discussed below. A combination therapy of archazolid with statins targets cholesterol metabolism in two different ways, thus enabling dose reduction of the single compounds while maintaining or even enhancing therapeutic effectiveness together with reduction of adverse effects.

4.3. Blocking cholesterol uptake and synthesis - a combination therapy as promising anti-cancer strategy

In the present work, we report V-ATPase inhibition as a novel way to achieve restriction of free cholesterol and lipid-raft disruption. As discussed above, alterations in cholesterol metabolism play a major role in cancer but exploitation as therapeutic target still remains challenging. Several different strategies to target aberrant cholesterol metabolism are currently under investigation: targeting cholesterol synthesis, reducing cholesterol uptake, interfering with intracellular cholesterol transport and inhibiting intestinal cholesterol absorption (81). For instance, a preclinical study showed a beneficial effect of ezetimibe, an inhibitor of intestinal cholesterol absorption, on prostate tumor growth (83). Also targeting prenylation by small molecules like an inhibitor of the geranylgeranyltransferase I or disruption of intracellular cholesterol transport by leelamine showed promising results (84,85). Leelamine is a lysosomotropic compound which inhibits cholesterol release from lysosomes and thereby causes membrane cholesterol depletion preferentially in cancer cells (85). In agreement with this finding, we observed that lysosomal trapping of cholesterol leads to a cholesterol depletion of the plasma membrane. We propose that archazolid targets cholesterol uptake by blocking LDL internalization and sequestering cholesterol within the lysosomes, thereby representing a new compound to target cellular cholesterol metabolism.
Extensive research has been done in evaluating the potential role of statins, cholesterol synthesis inhibitors, in cancer treatment, nevertheless the results remain controversial and further studies need to be performed (37,86). In the context of HCC, several studies show beneficial effects of statins either in single treatment or in combination treatment regimens (87). Sutter et al. for instance showed that various statins inhibited the proliferation of HCC by apoptosis induction and cell cycle arrest (88). Interestingly, Yang et al. found in a variety of different cell lines, that atorvastatin inhibits the growth of HCC, yet also induces autophagy as survival mechanism. In a combination therapy approach they blocked autophagy using the V-ATPase inhibitor bafilomycin, thereby enhancing atorvastatin-induced apoptosis (89). Along this line, we show that combining archazolid with simvastatin led to a synergistic enhancement of the anti-proliferative effect of archazolid single treatment. Additionally, apoptosis induction was increased by using the combination treatment. However, these effects were limited to our *in vitro* experiments. In our *in vivo* mouse xenograft model, we surprisingly found slightly induced tumor growth in simvastatin single treated mice and consequently no beneficial effect of a combination treatment. We hypothesize that this finding results from increased angiogenesis caused by simvastatin. Despite the existence of some pre-clinical studies that propose statins can inhibit tumor growth by reducing angiogenesis (90,91), others report pro-angiogenic properties of statins. Chen et al showed an improved outcome of rats suffering from stroke through administration of statins, which increased VEGF signaling and angiogenesis (92). In another study, Chade et al. showed that statins restore angiogenesis and attenuate intrarenal microvascular remodeling in a pig model for renal ischemia. In their study, simvastatin enhanced both intrarenal angiogenesis and arteriogenesis by increasing angiogenic growth factor expression and hypoxia-inducible factor-1α signaling (93). Interestingly, a biphasic dose-dependent effect of statins on angiogenesis has been reported by Weis et al. In their study on endothelial cells, they found angiogenesis promoting effects at low therapeutic concentrations but in contrast angiostatic effects at high concentrations. (94) The presence of such a dose-dependency could explain our observation of a clear anti-cancer effect *in vitro*, but not *in vivo*. In our *in vitro* experiments we only assessed the effect of simvastatin on cancer cells, while i.p. administration *in vivo* also targets endothelial cells. We hypothesize that the simvastatin plasma levels in our mouse model favored angiogenesis, which subsequently promoted tumor cell growth in a greater extent
than the growth inhibitory effect on the cancer cells directly. However, further data addressing this discrepancy is needed to draw a final conclusion.

This study and the data of others provide strong experimental evidence for the use of statins to treat HCC, yet like in our mouse model, the situation in vivo, especially in humans is vastly more complex. There are several human studies which evaluated the potential effect of statins on the development and treatment of HCC, of which some report a promising statin effect (87,95). However, more randomized controlled trials are necessary to clarify the role of statins in HCC.

In conclusion, our observation of synergistic growth inhibition by targeting the cholesterol metabolism in two ways, together with the research of others strongly suggest that a combination therapy approach might be superior to single agents in the treatment of HCC. Yet, dosage and treatment regimens still need further evaluation.

4.4. Inhibition of Ras signaling - new treatment option for an old oncogene

We report a change in biophysics and cholesterol metabolism upon V-ATPase inhibition, yet to our knowledge little to nothing is known on how this could influence proliferation of human cells. Interestingly, Atilla-Gokcumen et al. recently found first evidence, that cells tightly regulate lipid species and localization during the cell cycle by excessive feedback loops, leading to variations in cell stiffness along the cell cycle (96). This finding raises the question, on whether proliferative signaling is influenced by stiffness alterations. As an essential component of lipid-rafts, cholesterol has already been implicated in the regulation of different signaling pathways in cell survival and apoptosis. Cholesterol depletion in fibroblasts led to an induction of caspase 3 activity and apoptosis via a RhoA and p38 MAPK dependent pathway (49), which goes in line with the finding that Fas and TRAIL dependent apoptosis are lipid-raft dependent in cancer cells (48). Also anoikis-like apoptosis via FAK down-regulation has been observed upon cholesterol depletion and subsequent disruption of caveolae, a sub-type of lipid-rafts. (97). Yet, in our study a different mechanism must be present. On the one hand, we only see mild induction of apoptosis with a maximum of about 25 % in combination treatment with archazolid and simvastatin and on the other hand due to the fact that HUH-7 and HepG2 cells do not express caveolin (98). Additionally, cell survival is greatly determined on growth factor receptor signaling, like the insulin receptor and the EGF receptor (EGFR), which
have been reported to be regulated by cholesterol (44). EGFR dimer formation and the following autophosphorylation of was modulated by cholesterol (44). In an earlier study by our group we could also observe mislocalization of EGFR and a reduction of Rac1 dependent regulation after V-ATPase inhibition (23) however, the effects of cholesterol were not investigated in this study. Noteworthy, EGFR activation leads to an induction of proliferative Ras signaling.

The Ras family of small GTP-ases, was among the first proteins identified with the ability to induce cell growth and soon discovered to be aberrant in tumor cells (50). Ever since, many approaches have been made to specifically target de-regulated Ras signaling, but so far still face major drawbacks. This is caused by the enormous complexity of Ras signaling and activation, which is why Ras is still considered ‘undruggable’ (99). Major problems in finding small-molecule inhibitors are the high similarity amongst Ras family members and the fact that one Ras protein usually has several regulators, as well as several effectors (100). Yet, a more promising way in targeting Ras might be interfering with Ras localization (99), as it has become evident that different Ras isoforms are targeted to distinct membrane localizations and cause different activation of downstream effectors (52,100,101).

In mammalian cells, three different genes code for four proteins of the Ras family: H-Ras, N-Ras and two different splice variants of K-Ras (K-Ras4A and K-Ras4B) (101). There is significant variation in the contribution of Ras isoforms to the total aberrant Ras activation in different cancer cell lines, however, the major mutated isoform is K-Ras, followed by N-Ras and last H-Ras (102). Nevertheless, in HCC Ras is only mutated in few cases and rather downstream signaling is altered (53,54). Interestingly, there is now evidence that the different isoforms, which have long been thought to signal mainly form plasma membrane locations, are specifically targeted to specific endomembranes and different sites within the plasma membrane and that correct localization is essential to facilitate a variety of downstream signals (52,101). Nevertheless, there is still controversy as to which isoform is located at which membrane and how localization is linked to different downstream signaling (103).

Targeting of Ras to specific membrane sites is achieved by posttranslational modification of the proteins. All three Ras proteins undergo prenylation at their conserved C-terminal CAAX motif (C is cysteine, A is any aliphatic amino acid and X represents any amino acid), leading to ER targeting. N-Ras, H-Ras and K-Ras4A are additionally palmitoylated in the Golgi apparatus and transferred to the plasma
membrane, whereas K-Ras4B does not need additional palmitoylation as its membrane binding is mediated via a polybasic, lysine-rich region. (104) Besides signaling from plasma membrane locations, Ras signaling can also take place on membranes of the Golgi apparatus, the ER and mitochondria each having a different signaling outcome (50,101,105-108). Studies specifically evaluating plasma membrane Ras signaling show that N-Ras and H-Ras are dependent on a functional endocytosis pathway, while K-Ras signaling is not (102,103). In this regard another study reports that EGF activates N-Ras, but not K-Ras, however is enabled to activate both upon cholesterol depletion (100).

We report that upon V-ATPase inhibition the activation of Ras is diminished, leading to impaired downstream signaling namely Raf/MEK/ERK. Yet, we did not distinguish between different Ras isoforms or mutation status. Our study also shows that Ras signaling from plasma membrane lipid-rafts is inhibited by cholesterol depletion as external cholesterol supplementation restored Ras activation. The independence of K-Ras signaling form cholesterol depletion (102,103) might be the reason why the PI3K/Akt pathway in our experiment was not affect though. Yet there is still controversy on which Ras isoforms are more prone to activate Raf-1 or PI3K respectively. While Yan et al. report that K-Ras preferentially induces Raf-1 or H-Ras PI3K (109), Matallanas et al. state that Raf-1 is mainly activated at lipid-rafts (107). So it still has to be clarified which Ras isoform is responsible for the effect we report. Furthermore, cell types with different Ras mutation status should be analyzed to assess, whether our findings provide a therapeutic approach for tumors with specific Ras mutations. Reduced Ras/Raf/MEK/ERK signaling led to a reduction in proliferation in vitro and in vivo in our experiments, possibly indicating that inhibition of plasma membrane originated Ras signaling is mainly affected as Golgi apparatus dependent Ras signaling has been reported to be insufficient to promote cell proliferation (107).

We think that our results display V-ATPase inhibition as novel option to target lipid-raft dependent Ras signaling ultimately upstream, thereby avoiding specificity and pathway cross talk problems with small molecule inhibitors.
4.5. Concluding remarks and future perspectives

Despite intensive research, new strategies for treatment of HCC are still lacking. While research in the past mostly focused on direct inhibition of oncogenic signaling, targeting cancer cell lipid and cholesterol metabolism, especially in HCC is gaining interest. In the present work, we identified new treatment options for HCC by combining biophysical and cell-biological methods. We demonstrate for the first time that the V-ATPase inhibitor archazolid leads to lysosomal trapping of cholesterol, thereby altering cell stiffness and membrane fluidity. This subsequently leads to decreased proliferation by interference with membrane-related signaling of the well-known oncogene Ras (Fig 25). The in vivo efficacy of archazolid in a mouse xenograft HCC model seems to be based on cholesterol trapping as well. Importantly, non-malignant hepatocyte-like cells are not affected by the drug. We propose targeting cholesterol metabolism by V-ATPase-inhibition to be an attractive therapeutic strategy against HCC, which especially might overcome the present challenges in targeting oncogenic Ras signaling.

In a combination therapy approach, we applied the cholesterol synthesis inhibitor simvastatin together with archazolid and could report synergistic inhibition of cell proliferation and induction of apoptosis in vitro. Yet, the approach failed to be beneficial in our mouse model, which might be attributed to a pro-angiogenic effect of simvastatin. In conclusion, we think that a combination therapy of archazolid and simvastatin could target cholesterol metabolism and oncogenic Ras signaling in multiple ways and enhance the therapeutic effectiveness (Fig 25). However, future research needs to be done to fine-tune dosage and treatment regimen.
DISCUSSION

Figure 25 Proposed mechanism of action (A) Under physiological conditions LDL binds to its receptor and is internalized. The V-ATPase acidifies the endo-lysosome, leading to LDL dissociation from the receptor and cleavage. Free cholesterol is then released into the cytosol and is used as building block and for the integration into membranes. Furthermore, cholesterol is synthesized in the cytosol via the mevalonate pathway (brown bullets). Ras is a membrane-bound small GTPase mainly localized in cholesterol-enriched membrane microdomains, where it can be activated. Ras in turn activates different signaling pathways leading to proliferation and tumor growth. (B) Upon inhibition of the V-ATPase by Archazolid, LDLR internalization and acidification of the endo-lysosome is inhibited, causing subsequent accumulation of cholesterol within the lysosomes. Due to blocking the conversion of HMG-CoA to mevalonate by simvastatin, de novo synthesis of free cholesterol is inhibited. The lack of free cholesterol leads to cholesterol depletion of the membrane and subsequently a disruption of cholesterol-enriched microdomains and a change in membrane properties. As a consequence, cholesterol microdomain-dependent Ras cannot be activated anymore and downstream signaling is inhibited, leading to reduced proliferation and tumor growth. Mev Mevalonate, GPP geranlypyrophosphate, FPP farneslypyrophosphate, Sq Squalene, Lano Lanosterol, GEF guanosyl-exchange factor, GAP GTPase activating protein, LDL(R) low density lipoprotein (receptor)
5. REFERENCES

REFERENCES

REFERENCES

REFERENCES


64. Muro E, Atilla-Gokcumen GE, Eggert US. Lipids in cell biology: how can we understand them better? Molecular biology of the cell 2014;25(12):1819-23.


REFERENCES


APPENDIX
6. APPENDIX

6.1. Abbreviations

°C  degree Celsius
µg/mg/kg  micro/milli/kilo gram(s)
µl/ml  micro/milli liter(s)
Akt  protein kinase B
arch  archazolid
ATP  adenosine triphosphate
Bad  Bcl-2-antagonist of cell death
BC  bichininonic acid
BSA  bovine serum albumine
CE  cholesteryl ester
CO₂  carbon dioxide
CoA  coenzyme A
d  day(s)
DMEM  dulbecco’s modified eagle medium
DMSO  dimethylsulfoxide
DNA  desoxyribonucleic acid
DTT  dithioetherithol
ECL  enhanced chemiluminescence
EDTA  ethylenediaminetetraacetic acid
EGF(R)  epidermal growth factor (receptor)
EGTA  ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid
ER  endoplasmatic reticulum
ERK  extracellular signal-regulated kinase
FAK  focal adhesion kinase
Fas  a transmembrane protein of the tumor necrosis factor family
FCS  fetal calf serum
FRAP  fluorescence recovery after photo-bleaching
g  gravity
Ga  gauge
GAP  GTP-ase activating protein
GDP  guanosine diphosphate
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEF</td>
<td>guanosyl-exchange factor</td>
</tr>
<tr>
<td>GFP</td>
<td>green fluorescent protein</td>
</tr>
<tr>
<td>GP</td>
<td>generalized polarization</td>
</tr>
<tr>
<td>GRB2</td>
<td>Growth factor receptor-bound protein 2</td>
</tr>
<tr>
<td>GTP</td>
<td>guanosine triphosphate</td>
</tr>
<tr>
<td>h</td>
<td>hour(s)</td>
</tr>
<tr>
<td>H$_2$O$_2$</td>
<td>hydrogen peroxide</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular carcinoma</td>
</tr>
<tr>
<td>Hep3B</td>
<td>liver cancer cell line</td>
</tr>
<tr>
<td>HepG2</td>
<td>liver cancer cell line</td>
</tr>
<tr>
<td>hHep</td>
<td>primary human hepatocytes</td>
</tr>
<tr>
<td>HMG-CoA</td>
<td>3-Hydroxy-3-Methylglutaryl-CoA</td>
</tr>
<tr>
<td>HMGCR</td>
<td>3-Hydroxy-3-Methylglutaryl-CoA reductase</td>
</tr>
<tr>
<td>Hoechst</td>
<td>Hoechst 33342, bisBenzimide</td>
</tr>
<tr>
<td>HRP</td>
<td>horseradish preoxidase</td>
</tr>
<tr>
<td>HUH-7</td>
<td>liver cancer cell line</td>
</tr>
<tr>
<td>i.p.</td>
<td>intra peritoneal</td>
</tr>
<tr>
<td>IHC</td>
<td>immune histochemistry</td>
</tr>
<tr>
<td>LAMP-1</td>
<td>lysosomal-associated membrane protein 1</td>
</tr>
<tr>
<td>LDL (R)</td>
<td>low density lipoprotein (receptor)</td>
</tr>
<tr>
<td>LX-R</td>
<td>liver X receptor</td>
</tr>
<tr>
<td>MEK</td>
<td>mitogen-activated protein kinase kinase</td>
</tr>
<tr>
<td>min</td>
<td>minute(s)</td>
</tr>
<tr>
<td>mRNA</td>
<td>messenger RNA</td>
</tr>
<tr>
<td>n/cm</td>
<td>nano/centi meter(s)</td>
</tr>
<tr>
<td>Na$_3$VO$_4$</td>
<td>sodium orthovanadate</td>
</tr>
<tr>
<td>NaCl</td>
<td>sodium chloride</td>
</tr>
<tr>
<td>NaF</td>
<td>sodium fluoride</td>
</tr>
<tr>
<td>nM/µM/mM</td>
<td>nano/micro/milli molar</td>
</tr>
<tr>
<td>P</td>
<td>phosphate</td>
</tr>
<tr>
<td>P/S</td>
<td>penicillin streptomycin</td>
</tr>
<tr>
<td>p38 MAPK</td>
<td>p38 mitogen-activated protein kinase</td>
</tr>
<tr>
<td>PBS</td>
<td>phosphate buffered saline</td>
</tr>
<tr>
<td>PFA</td>
<td>para formaldehyde</td>
</tr>
</tbody>
</table>
PI  propidium iodide
PI3K  phosphoinositide 3-kinase
PLCe  1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase epsilon
PMA  phorbol myristate acetate
PMSF  phenylmethylsulfonylfluorid
PP  pyrophosphate
qPCR  quantitative real-time polymerase chain reaction
Raf  rapidly accelerated fibrosarcoma or rat fibrosarcoma
RalGDS  Ral guanine nucleotide dissociation stimulator
Ras  rat sarcoma
RhoA  Ras homolog gene family member A
RNA  ribonucleic acid
rpm  rotations per minute
RT-DC  real-time deformability cytometry
s  second(s)
SCID  severe combined immune deficiency
SDS  sodium dodecyl sulfate
siRNA  small-interfering RNA
SOS  son of sevenless
SREBP-2  sterol-regulatrory element binding protein 2
STR  short tandem repeat
TCE  trichloroethanol
TRAIL  tumor necrosis factor related apoptosis inducing ligand
U/ml  unit per milliliter
V-ATPase  vacuolar-type ATPase
VLDL  very low density lipoprotein
w/v  weight per volume
6.2. Publications

6.2.1. Articles

Karin Bartel, Maria Winzi, Melanie Ulrich, Andreas Koeberle, Dirk Menche, Oliver Werz, Rolf Müller, Jochen Guck, Angelika M. Vollmar, Karin von Schwarzenberg, “V-ATPase inhibition increases cancer cell stiffness and blocks membrane related - Ras signaling - a new option for HCC therapy”, 2016, Oncotarget (110)


6.2.2. Oral presentations

Karin Steiner, Angelika M. Vollmar, Karin von Schwarzenberg, “V-ATPase inhibition by archazolid A influences cholesterol metabolism of cancer cells”, 2nd European Conference on Natural Products, September 6-9th, 2015, Frankfurt, Germany

Karin Steiner, Angelika M. Vollmar, Karin von Schwarzenberg, “Effect of Archazolid A on metabolism in HCC”, FOR 1406 Meeting, June 30th - July 1st, 2015, Saarbrücken, Germany

Karin Steiner, Angelika M. Vollmar, Karin von Schwarzenberg, “Effect of Archazolid A on metabolism in hepatocellular carcinoma cell lines”, FOR 1406 Meeting, January 8-9th, 2015, Munich, Germany

6.2.3. Poster presentations


Karin Bartel, Maria Winzi, Melanie Ulrich, Andreas Koeberle, Dirk Menche, Oliver Werz, Rolf Müller, Jochen Guck, Angelika M. Vollmar, Karin von Schwarzenberg, “Targeting cholesterol metabolism in hepatocellular carcinoma - V-ATPase inhibition as a novel therapeutic option”, DPHG annual meeting 2016, October 4-6th, 2016, Munich, Germany

Karin Steiner, Rolf Müller, Angelika M. Vollmar, Karin von Schwarzenberg, “V-ATPase inhibition by Archazolid A influences cholesterol metabolism of cancer cells”, HIPS Symposium, July 2nd, 2015, Saarbrücken, Germany


Karin Steiner, Angelika M. Vollmar, Karin von Schwarzenberg, “Synergistic effects of Archazolid A and Simvastatin on hepatocellular carcinoma cells”, Graduate School of Natural Product Research Summer Symposium, July 9th, 2014, Saarbrücken, Germany
6.3. Acknowledgements

Mein größter Dank gilt Frau Professor Vollmar für die Möglichkeit meine Doktorarbeit an Ihrem Lehrstuhl anfertigen zu können. Ich möchte mich für Ihr anhaltendes Vertrauen und die ausgezeichneten Ratschläge, sowohl in fachlichen, als auch in persönlichen Angelegenheiten bedanken. Mit Ihrem Eifer für die Wissenschaft und die Lehre sind Sie für mich ein großes Vorbild.


Einen großen Dank auch an Prof. Dr. Christian Wahl-Schott und Prof. Dr. Ernst Wagner für Ihre Rolle als Dritt- und Viertprüfer. Danke auch an Herrn PD Dr. Michalakis und Prof. Dr. Franz Paintner, als Fünft- und Sechstprüfer für das Interesse an meiner Arbeit.


Ein großer Dank gilt auch allen Mitarbeitern unseres Arbeitskreises. Es herrschte immer ein offenes und sehr gutes Betriebsklima, das keinen Falls selbstverständlich ist. Die gute Stimmung und das gute Verhältnis erstreckte sich auch weit über die Arbeit hinaus in die Freizeit, was es jeden Morgen umso einfacher machte in die Arbeit und gleichzeitig zu Freunden zu gehen. Besonders lieben Dank an dieser Stelle an Fabi, Meli und Chrissi für die tolle Zeit im Studium, im Labor und bei so vielen tollen Erlebnissen außerhalb. Danke auch Flo und Max für die schöne Zeit.

Last, but not least: An dieser Stelle möchte ich mich bei meiner Familie und meinem Mann bedanken.

Liebe Mama, eigentlich fehlen mir die Worte, um meinen Dank auszudrücken. Danke für deine grenzenlose Unterstützung vom Kindergarten bis zum Studium. Besonders in unseren schwersten Zeiten als wir Sigi verloren und deine Erkrankung überstanden haben, warst du für mich nicht nur Mama, sondern auch immer beste Freundin.


In guten, wie in schweren Tagen.

Danke, dass ihr immer an mich geglaubt und mich unterstützt habt, ohne euch wäre das alles nicht möglich gewesen!